{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T10:02:45Z","timestamp":1789639365436,"version":"4.0.0"},"reference-count":271,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s40265-024-02062-z","type":"journal-article","created":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T02:02:43Z","timestamp":1722477763000},"page":"1071-1091","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Drug-Induced Pigmentation: A Review"],"prefix":"10.1007","volume":"84","author":[{"given":"Aaron","family":"Tisack","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7693-4729","authenticated-orcid":false,"given":"Tasneem F.","family":"Mohammad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,1]]},"reference":[{"issue":"4","key":"2062_CR1","doi-asserted-by":"publisher","first-page":"253","DOI":"10.2165\/00128071-200102040-00006","volume":"2","author":"O Dereure","year":"2001","unstructured":"Dereure O. Drug-induced skin pigmentation. Epidemiology, diagnosis and treatment. Am J Clin Dermatol. 2001;2(4):253\u201362.","journal-title":"Am J Clin Dermatol"},{"issue":"7","key":"2062_CR2","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1111\/j.1468-3083.2010.03904.x","volume":"25","author":"SK Tan","year":"2011","unstructured":"Tan SK. Exogenous ochronosis in ethnic Chinese Asians: a clinicopathological study, diagnosis and treatment. J Eur Acad Dermatol Venereol. 2011;25(7):842\u201350.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"7","key":"2062_CR3","first-page":"644","volume":"11","author":"W Krause","year":"2013","unstructured":"Krause W. Drug-induced hperpigemntation: a systematic review. J Dtsch Dermatol Ges. 2013;11(7):644\u201351.","journal-title":"J Dtsch Dermatol Ges"},{"issue":"1","key":"2062_CR4","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s40257-018-0393-2","volume":"20","author":"AF Nahhas","year":"2019","unstructured":"Nahhas AF, Braunberger TL, Hamzavi IH. An update on drug-induced pigmentation. Am J Clin Dermatol. 2019;20(1):75\u201396.","journal-title":"Am J Clin Dermatol"},{"issue":"4","key":"2062_CR5","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/S0190-9622(87)70101-7","volume":"16","author":"S Waitzer","year":"1987","unstructured":"Waitzer S, Butany J, From L, Hanna W, Ramsay C, Downar E. Cutaneous ultrastructural changes and photosensitivity associated with amiodarone therapy. J Am Acad Dermatol. 1987;16(4):779\u201387.","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"2062_CR6","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.36849\/JDD.7409","volume":"22","author":"K Young","year":"2023","unstructured":"Young K, Pagan AD, Yoon J, Getachew E, Leung B, Nguyen N, et al. Seasonal patterns in tetracycline-associated hyperpigmentation among patients with acne vulgaris. J Drugs Dermatol. 2023;22(11):e9\u201311.","journal-title":"J Drugs Dermatol"},{"issue":"6","key":"2062_CR7","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s40257-021-00632-5","volume":"22","author":"LL Guan","year":"2021","unstructured":"Guan LL, Lim HW, Mohammad TF. Sunscreens and photoaging: a review of current literature. Am J Clin Dermatol. 2021;22(6):819\u201328.","journal-title":"Am J Clin Dermatol"},{"issue":"9","key":"2062_CR8","first-page":"1201","volume":"30","author":"TS Alster","year":"2004","unstructured":"Alster TS, Gupta SN. Minocycline-induced hyperpigmentation treated with a 755-nm Q-switched alexandrite laser. Dermatol Surg. 2004;30(9):1201\u20134.","journal-title":"Dermatol Surg"},{"issue":"7\u20138","key":"2062_CR9","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1080\/14764172.2017.1418514","volume":"20","author":"T Barrett","year":"2018","unstructured":"Barrett T, de Zwaan S. Picosecond alexandrite laser is superior to Q-switched Nd:YAG laser in treatment of minocycline-induced hyperpigmentation: a case study and review of the literature. J Cosmet Laser Ther. 2018;20(7\u20138):387\u201390.","journal-title":"J Cosmet Laser Ther"},{"issue":"3","key":"2062_CR10","first-page":"205","volume":"28","author":"IS Friedman","year":"2002","unstructured":"Friedman IS, Shelton RM, Phelps RG. Minocycline-induced hyperpigmentation of the tongue: successful treatment with the Q-switched ruby laser. Dermatol Surg. 2002;28(3):205\u20139.","journal-title":"Dermatol Surg"},{"issue":"4","key":"2062_CR11","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1002\/(SICI)1096-9101(1998)22:4<223::AID-LSM7>3.0.CO;2-R","volume":"22","author":"B Greve","year":"1998","unstructured":"Greve B, Schonermark MP, Raulin C. Minocycline-induced hyperpigmentation: treatment with the Q-switched Nd:YAG laser. Lasers Surg Med. 1998;22(4):223\u20137.","journal-title":"Lasers Surg Med"},{"key":"2062_CR12","doi-asserted-by":"publisher","first-page":"253","DOI":"10.2147\/CCID.S394754","volume":"16","author":"Y Li","year":"2023","unstructured":"Li Y, Zhen X, Yao X, Lu J. Successful treatment of minocycline-induced facial hyperpigmentation with a combination of chemical peels and intense pulsed light. Clin Cosmet Investig Dermatol. 2023;16:253\u20136.","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"12","key":"2062_CR13","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1177\/0961203317700486","volume":"26","author":"E Bahloul","year":"2017","unstructured":"Bahloul E, Jallouli M, Garbaa S, Marzouk S, Masmoudi A, Turki H, et al. Hydroxychloroquine-induced hyperpigmentation in systemic diseases: prevalence, clinical features and risk factors: a cross-sectional study of 41 cases. Lupus. 2017;26(12):1304\u20138.","journal-title":"Lupus"},{"issue":"9","key":"2062_CR14","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1001\/jamadermatol.2013.5107","volume":"149","author":"I Braunstein","year":"2013","unstructured":"Braunstein I, Wanat KA, Elenitsas R, Xu X, Frey N, Rosenbach M. Eltrombopag-associated hyperpigmentation. JAMA Dermatol. 2013;149(9):1112\u20135.","journal-title":"JAMA Dermatol"},{"issue":"4","key":"2062_CR15","doi-asserted-by":"publisher","first-page":"332","DOI":"10.3109\/15569527.2011.647178","volume":"31","author":"Z Takci","year":"2012","unstructured":"Takci Z, Ozoguz P. Nail discoloration due to tinzaparin sodium. Cutan Ocul Toxicol. 2012;31(4):332\u20134.","journal-title":"Cutan Ocul Toxicol"},{"issue":"3","key":"2062_CR16","doi-asserted-by":"publisher","first-page":"6","DOI":"10.5070\/D32197W4T4","volume":"9","author":"N Scheinfeld","year":"2003","unstructured":"Scheinfeld N. Phenytoin in cutaneous medicine: its uses, mechanisms and side effects. Dermatol Online J. 2003;9(3):6.","journal-title":"Dermatol Online J"},{"issue":"2","key":"2062_CR17","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1740-2557-2-11","volume":"22","author":"MR Namazi","year":"2005","unstructured":"Namazi MR. Phenytoin as a novel anti-vitiligo weapon. J Autoimmune Dis. 2005;22(2):11.","journal-title":"J Autoimmune Dis."},{"issue":"1","key":"2062_CR18","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1177\/2042098614560736","volume":"6","author":"S Clark","year":"2015","unstructured":"Clark S, Antell A, Kaufman K. New antiepileptic medication linked to blue discoloration of the skin and eyes. Ther Adv Drug Saf. 2015;6(1):15\u20139.","journal-title":"Ther Adv Drug Saf."},{"issue":"9","key":"2062_CR19","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1001\/jamadermatol.2013.8895","volume":"150","author":"T Garin Shkolnik","year":"2014","unstructured":"Garin Shkolnik T, Feuerman H, Didkovsky E, Kaplan I, Bergman R, Pavlovsky L, et al. Blue-gray mucocutaneous discoloration: a new adverse effect of ezogabine. JAMA Dermatol. 2014;150(9):984\u20139.","journal-title":"JAMA Dermatol"},{"key":"2062_CR20","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ebcr.2017.01.001","volume":"7","author":"SV Mathias","year":"2017","unstructured":"Mathias SV, Abou-Khalil BW. Ezogabine skin discoloration is reversible after discontinuation. Epilepsy Behav Case Rep. 2017;7:61\u20133.","journal-title":"Epilepsy Behav Case Rep."},{"issue":"1","key":"2062_CR21","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s12903-015-0102-y","volume":"15","author":"NG Beacher","year":"2015","unstructured":"Beacher NG, Brodie MJ, Goodall C. A case report: retigabine induced oral mucosal dyspigmentation of the hard palate. BMC Oral Health. 2015;15(1):122.","journal-title":"BMC Oral Health"},{"issue":"6","key":"2062_CR22","doi-asserted-by":"publisher","first-page":"838","DOI":"10.4103\/0019-5154.370349","volume":"67","author":"YS Pathania","year":"2022","unstructured":"Pathania YS, Mudugal R, Budania A. Valproic acid monotherapy induced longitudinal melanonychia. Indian J Dermatol. 2022;67(6):838.","journal-title":"Indian J Dermatol"},{"issue":"1","key":"2062_CR23","doi-asserted-by":"publisher","first-page":"96","DOI":"10.3109\/15569527.2016.1156121","volume":"36","author":"B Solak","year":"2017","unstructured":"Solak B, Oztas Kara R, Erdem T. Various simultaneous nail changes due to valproic acid use. Cutan Ocul Toxicol. 2017;36(1):96\u20137.","journal-title":"Cutan Ocul Toxicol"},{"key":"2062_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2023.113660","volume":"263","author":"A Elwadhi","year":"2023","unstructured":"Elwadhi A, Neha KC, Gupta D, Sharawat IK, Panda PK. Sodium valproate-induced hyperpigmentation. J Pediatr. 2023;263: 113660.","journal-title":"J Pediatr"},{"issue":"1","key":"2062_CR25","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3109\/15569527.2010.521225","volume":"30","author":"T Skare","year":"2011","unstructured":"Skare T, Ribeiro CF, Souza FH, Haendchen L, Jord\u00e3o JM. Antimalarial cutaneous side effects: a study in 209 users. Cutan Ocul Toxicol. 2011;30(1):45\u20139.","journal-title":"Cutan Ocul Toxicol"},{"issue":"7","key":"2062_CR26","doi-asserted-by":"publisher","first-page":"e266","DOI":"10.1111\/j.1365-2230.2008.03185.x","volume":"34","author":"CB Gallo","year":"2009","unstructured":"Gallo CB, Luiz AC, Ferrazzo KL, Migliari DA, Sugaya NN. Drug-induced pigmentation of hard palate and skin due to chronic chloroquine therapy: report of two cases. Clin Exp Dermatol. 2009;34(7):e266\u20137.","journal-title":"Clin Exp Dermatol"},{"issue":"12","key":"2062_CR27","doi-asserted-by":"publisher","first-page":"20723","DOI":"10.5070\/D31912020723","volume":"19","author":"A Mir","year":"2013","unstructured":"Mir A, Boyd KP, Meehan SA, McLellan B. Hydroxycholoroquine-induced hyperpigmentation. Dermatol Online J. 2013;19(12):20723.","journal-title":"Dermatol Online J"},{"issue":"2","key":"2062_CR28","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.jaad.2020.04.024","volume":"83","author":"AN Sharma","year":"2020","unstructured":"Sharma AN, Mesinkovska NA, Paravar T. Characterizing the adverse dermatologic effects of hydroxychloroquine: a systematic review. J Am Acad Dermatol. 2020;83(2):563\u201378.","journal-title":"J Am Acad Dermatol"},{"key":"2062_CR29","doi-asserted-by":"publisher","first-page":"469","DOI":"10.4269\/ajtmh.1945.s1-25.469","volume":"25","author":"VW Lippard","year":"1945","unstructured":"Lippard VW, Kauer GL Jr. Pigmentation of the palate and subungual tissues associated with suppressive quinacrine hydrochloride therapy. Am J Trop Med Hyg. 1945;25:469\u201371.","journal-title":"Am J Trop Med Hyg"},{"issue":"2","key":"2062_CR30","first-page":"e74","volume":"60","author":"M da Mota Vasconcelos Brasil","year":"2012","unstructured":"da Mota Vasconcelos Brasil M, Ribeiro CM, Fonseca DD, Gueiros LA, Leao JC. Chloroquine-induced hyperpigmentation of the hard palate. Gen Dent. 2012;60(2):e74\u20138.","journal-title":"Gen Dent"},{"key":"2062_CR31","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jdcr.2020.10.030","volume":"7","author":"JW Ricardo","year":"2021","unstructured":"Ricardo JW, Chikeka I, Silvers DN, Lipner SR. Longitudinal melanonychia and skin hyperpigmentation associated with hydroxychloroquine therapy. JAAD Case Rep. 2021;7:23\u20135.","journal-title":"JAAD Case Rep."},{"issue":"6","key":"2062_CR32","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1111\/j.1365-2710.2008.00955.x","volume":"33","author":"MA Melikoglu","year":"2008","unstructured":"Melikoglu MA, Melikoglu M, Gurbuz U, Budak BS, Kacar C. Hydroxychloroquine-induced hyperpigmentation: a case report. J Clin Pharm Ther. 2008;33(6):699\u2013701.","journal-title":"J Clin Pharm Ther"},{"issue":"12","key":"2062_CR33","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1111\/j.1600-0560.2008.01004.x","volume":"35","author":"PK Puri","year":"2008","unstructured":"Puri PK, Lountzis NI, Tyler W, Ferringer T. Hydroxychloroquine-induced hyperpigmentation: the staining pattern. J Cutan Pathol. 2008;35(12):1134\u20137.","journal-title":"J Cutan Pathol"},{"issue":"4","key":"2062_CR34","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.ijwd.2020.06.009","volume":"6","author":"D Kwak","year":"2020","unstructured":"Kwak D, Grimes PE. A case of hyperpigmentation induced by hydroxychloroquine and quinacrine in a patient with systemic lupus erythematosus and review of the literature. Int J Womens Dermatol. 2020;6(4):268\u201371.","journal-title":"Int J Womens Dermatol."},{"issue":"2","key":"2062_CR35","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1080\/03009740701769735","volume":"37","author":"MJ Rood","year":"2008","unstructured":"Rood MJ, Vermeer MH, Huizinga TW. Hyperpigmentation of the skin due to hydroxychloroquine. Scand J Rheumatol. 2008;37(2):158.","journal-title":"Scand J Rheumatol"},{"key":"2062_CR36","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1001\/archderm.1963.01590220051006","volume":"88","author":"D Tuffanelli","year":"1963","unstructured":"Tuffanelli D, Abraham RK, Dubois EI. Pigmentation from antimalarial therapy. Its possible relationship to the ocular lesions. Arch Dermatol. 1963;88:419\u201326.","journal-title":"Arch Dermatol"},{"issue":"6","key":"2062_CR37","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/jid.1965.162","volume":"45","author":"WM Sams Jr","year":"1965","unstructured":"Sams WM Jr, Epstein JH. The affinity of melanin for chloroquine. J Investig Dermatol. 1965;45(6):482\u20137.","journal-title":"J Investig Dermatol"},{"issue":"12","key":"2062_CR38","first-page":"975","volume":"117","author":"A Ribrioux","year":"1990","unstructured":"Ribrioux A. Synthetic antimalarials and skin [in French]. Ann Dermatol Venereol. 1990;117(12):975\u201390.","journal-title":"Ann Dermatol Venereol"},{"key":"2062_CR39","doi-asserted-by":"publisher","first-page":"14","DOI":"10.11604\/pamj.2022.42.14.34956","volume":"42","author":"SD Chavhan","year":"2022","unstructured":"Chavhan SD, Jawade S. Clofazimine induced pigmentation in leprosy patches. Pan Afr Med J. 2022;42:14.","journal-title":"Pan Afr Med J"},{"issue":"5786","key":"2062_CR40","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1136\/bmj.4.5786.514","volume":"4","author":"AB Karat","year":"1971","unstructured":"Karat AB, Jeevaratnam A, Karat S, Rao PS. Controlled clinical trial of clofazimine in untreated lepromatous leprosy. Br Med J. 1971;4(5786):514\u20136.","journal-title":"Br Med J"},{"issue":"11","key":"2062_CR41","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1111\/j.1469-0691.2011.03716.x","volume":"18","author":"HB Xu","year":"2012","unstructured":"Xu HB, Jiang RH, Xiao HP. Clofazimine in the treatment of multidrug-resistant tuberculosis. Clin Microbiol Infect. 2012;18(11):1104\u201310.","journal-title":"Clin Microbiol Infect"},{"issue":"9","key":"2062_CR42","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1093\/cid\/civ027","volume":"60","author":"S Tang","year":"2015","unstructured":"Tang S, Yao L, Hao X, Liu Y, Zeng L, Liu G, et al. Clofazimine for the treatment of multidrug-resistant tuberculosis: prospective, multicenter, randomized controlled study in China. Clin Infect Dis. 2015;60(9):1361\u20137.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"2062_CR43","doi-asserted-by":"publisher","first-page":"1602445","DOI":"10.1183\/13993003.02445-2016","volume":"49","author":"M Dalcolmo","year":"2017","unstructured":"Dalcolmo M, Gayoso R, Sotgiu G, D\u2019Ambrosio L, Rocha JL, Borga L, et al. Effectiveness and safety of clofazimine in multidrug-resistant tuberculosis: a nationwide report from Brazil. Eur Respir J. 2017;49(3):1602445.","journal-title":"Eur Respir J"},{"issue":"3","key":"2062_CR44","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.jid.2017.09.031","volume":"138","author":"MD Murashov","year":"2018","unstructured":"Murashov MD, LaLone V, Rzeczycki PM, Keswani RK, Yoon GS, Sud S, et al. The physicochemical basis of clofazimine-induced skin pigmentation. J Invest Dermatol. 2018;138(3):697\u2013703.","journal-title":"J Invest Dermatol"},{"issue":"4","key":"2062_CR45","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.ijwd.2018.08.003","volume":"4","author":"N Leung","year":"2018","unstructured":"Leung N, Oliveira M, Selim MA, McKinley-Grant L, Lesesky E. Erythema dyschromicum perstans: a case report and systematic review of histologic presentation and treatment. Int J Womens Dermatol. 2018;4(4):216\u201322.","journal-title":"Int J Womens Dermatol."},{"issue":"9","key":"2062_CR46","first-page":"958","volume":"59","author":"P Burke","year":"2013","unstructured":"Burke P, Jahangir K, Kolber MR. Dapsone-induced methemoglobinemia: case of the blue lady. Can Fam Physician. 2013;59(9):958\u201361.","journal-title":"Can Fam Physician"},{"issue":"11","key":"2062_CR47","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1097\/SMJ.0b013e318232139f","volume":"104","author":"A Skold","year":"2011","unstructured":"Skold A, Cosco DL, Klein R. Methemoglobinemia: pathogenesis, diagnosis, and management. South Med J. 2011;104(11):757\u201361.","journal-title":"South Med J"},{"issue":"7","key":"2062_CR48","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.bbmt.2005.04.011","volume":"11","author":"D Sangiolo","year":"2005","unstructured":"Sangiolo D, Storer B, Nash R, Corey L, Davis C, Flowers M, et al. Toxicity and efficacy of daily dapsone as Pneumocystis jiroveci prophylaxis after hematopoietic stem cell transplantation: a case-control study. Biol Blood Marrow Transplant. 2005;11(7):521\u20139.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"2062_CR49","volume":"14","author":"A Afrin","year":"2022","unstructured":"Afrin A, Cohen PR. Doxycycline-associated hyperpigmentation: a case report and literature review. Cureus. 2022;14(4): e23754.","journal-title":"Cureus."},{"issue":"9","key":"2062_CR50","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1097\/01.inf.0000177283.71692.56","volume":"24","author":"M Akcam","year":"2005","unstructured":"Akcam M, Artan R, Akcam FZ, Yilmaz A. Nail discoloration induced by doxycycline. Pediatr Infect Dis J. 2005;24(9):845\u20136.","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"2062_CR51","first-page":"37","volume":"73","author":"SP Keijmel","year":"2015","unstructured":"Keijmel SP, van Kasteren ME, Blokx WA, van der Meer JW, van Rossum M, Bleeker-Rovers CP. Cutaneous hyperpigmentation induced by doxycycline: a case series. Neth J Med. 2015;73(1):37\u201340.","journal-title":"Neth J Med"},{"issue":"10","key":"2062_CR52","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1177\/1060028015598166","volume":"49","author":"E Dowlati","year":"2015","unstructured":"Dowlati E, Dovico J, Unwin B. Skin hyperpigmentation and melanonychia from chronic doxycycline use. Ann Pharmacother. 2015;49(10):1175\u20136.","journal-title":"Ann Pharmacother"},{"issue":"4","key":"2062_CR53","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/j.jaad.2022.10.007","volume":"88","author":"K Young","year":"2023","unstructured":"Young K, Pagan AD, Yoon J, Getachew E, Leung B, Nguyen N, et al. Differences in risk of tetracycline-associated hyperpigmentation between racial and ethnic groups in patients with acne vulgaris: a national US retrospective study. J Am Acad Dermatol. 2023;88(4):872\u20135.","journal-title":"J Am Acad Dermatol"},{"key":"2062_CR54","first-page":"1513","volume":"46","author":"BS Kim","year":"2008","unstructured":"Kim BS, Won TH, Seo PS, Park S. A case of generalized hyperpigmentation caused by antituberculosis drugs. Korean J Dermatol. 2008;46:1513\u20136.","journal-title":"Korean J Dermatol"},{"issue":"9","key":"2062_CR55","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1001\/jamadermatol.2013.4365","volume":"149","author":"M Lorente","year":"2013","unstructured":"Lorente M, Ballano A, Juanes A, Pastor MA, Cuevas J. Blue-gray pigmentation in trunk and extremities in a 71-year-old man. JAMA Dermatol. 2013;149(9):1111\u20132.","journal-title":"JAMA Dermatol"},{"issue":"12","key":"2062_CR56","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.annder.2017.05.017","volume":"144","author":"E Garval","year":"2017","unstructured":"Garval E, Vuiblet V, Durlach A, Perceau G, Anuset D, Bernard P. Skin pigmentation induced by meropenem and levofloxacin [in French]. Ann Dermatol Venereol. 2017;144(12):793\u20138.","journal-title":"Ann Dermatol Venereol"},{"key":"2062_CR57","doi-asserted-by":"publisher","first-page":"6186471","DOI":"10.1155\/2020\/6186471","volume":"2020","author":"SS Patil","year":"2020","unstructured":"Patil SS, Patil SM, Campbell R, Singh M, Plotkin M. Levofloxacin-induced acute hyperpigmentation changes in a chronic kidney disease patient. Case Rep Med. 2020;2020:6186471.","journal-title":"Case Rep Med"},{"issue":"7","key":"2062_CR58","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1001\/archderm.1995.01690190112032","volume":"131","author":"L Le Cleach","year":"1995","unstructured":"Le Cleach L, Chosidow O, Peytavin G, Berry JP, Boisnic S, Le Charpentier Y, et al. Blue-black pigmentation of the legs associated with pefloxacin therapy. Arch Dermatol. 1995;131(7):856\u20137.","journal-title":"Arch Dermatol"},{"issue":"6","key":"2062_CR59","doi-asserted-by":"publisher","first-page":"431","DOI":"10.2165\/00002018-199818060-00004","volume":"18","author":"D Eisen","year":"1998","unstructured":"Eisen D, Hakim MD. Minocycline-induced pigmentation. Incidence, prevention and management. Drug Saf. 1998;18(6):431\u201340.","journal-title":"Drug Saf"},{"issue":"8","key":"2062_CR60","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1002\/1529-0131(199908)42:8<1691::AID-ANR18>3.0.CO;2-S","volume":"42","author":"JR O'Dell","year":"1999","unstructured":"O\u2019Dell JR, Paulsen G, Haire CE, Blakely K, Palmer W, Wees S, et al. Treatment of early seropositive rheumatoid arthritis with minocycline: four-year followup of a double-blind, placebo-controlled trial. Arthritis Rheum. 1999;42(8):1691\u20135.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"2062_CR61","doi-asserted-by":"publisher","first-page":"24063","DOI":"10.3402\/jchimp.v4.24063","volume":"4","author":"V Fiscus","year":"2014","unstructured":"Fiscus V, Hankinson A, Alweis R. Minocycline-induced hyperpigmentation. J Community Hosp Intern Med Perspect. 2014;4(3):24063.","journal-title":"J Community Hosp Intern Med Perspect."},{"issue":"1","key":"2062_CR62","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/j.1365-2230.2004.01421.x","volume":"29","author":"RW Mouton","year":"2004","unstructured":"Mouton RW, Jordaan HF, Schneider JW. A new type of minocycline-induced cutaneous hyperpigmentation. Clin Exp Dermatol. 2004;29(1):8\u201314.","journal-title":"Clin Exp Dermatol"},{"issue":"5","key":"2062_CR63","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1016\/j.jaad.2007.04.028","volume":"57","author":"AR Bowen","year":"2007","unstructured":"Bowen AR, McCalmont TH. The histopathology of subcutaneous minocycline pigmentation. J Am Acad Dermatol. 2007;57(5):836\u20139.","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"2062_CR64","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/j.amjmed.2006.07.031","volume":"119","author":"AA Alkhatib","year":"2006","unstructured":"Alkhatib AA, Sessoms S. The tarnished tongue. Am J Med. 2006;119(10):832\u20134.","journal-title":"Am J Med"},{"issue":"2","key":"2062_CR65","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/S1079-2104(05)80279-3","volume":"79","author":"MA Meyerson","year":"1995","unstructured":"Meyerson MA, Cohen PR, Hymes SR. Lingual hyperpigmentation associated with minocycline therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1995;79(2):180\u20134.","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"issue":"3","key":"2062_CR66","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1001\/archderm.136.3.427","volume":"136","author":"EL Tanzi","year":"2000","unstructured":"Tanzi EL, Hecker MS. Minocycline-induced hyperpigmentation of the tongue. Arch Dermatol. 2000;136(3):427\u20138.","journal-title":"Arch Dermatol"},{"issue":"6","key":"2062_CR67","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1016\/S0161-6420(97)30204-8","volume":"104","author":"FT Fraunfelder","year":"1997","unstructured":"Fraunfelder FT, Randall JA. Minocycline-induced scleral pigmentation. Ophthalmology. 1997;104(6):936\u20138.","journal-title":"Ophthalmology"},{"issue":"11","key":"2062_CR68","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2018.3088","volume":"136","author":"SM Maloney","year":"2018","unstructured":"Maloney SM, Williams BK Jr, Shields CL. Long-term minocycline therapy with scleral pigmentation simulating melanocytosis. JAMA Ophthalmol. 2018;136(11): e183088.","journal-title":"JAMA Ophthalmol."},{"issue":"12","key":"2062_CR69","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1001\/archderm.1979.04010120001001","volume":"115","author":"RS Basler","year":"1979","unstructured":"Basler RS. Minocycline therapy for acne. Arch Dermatol. 1979;115(12):1391.","journal-title":"Arch Dermatol"},{"key":"2062_CR70","doi-asserted-by":"publisher","first-page":"7653","DOI":"10.2147\/IDR.S392818","volume":"15","author":"D Liu","year":"2022","unstructured":"Liu D, Niu J, Chen G, Xu L. Treatment of carbapenem-resistant multidrug-resistant gram-negative bacilli with intracerebroventricular injection of polymyxin B: a retrospective study. Infect Drug Resist. 2022;15:7653\u201366.","journal-title":"Infect Drug Resist."},{"issue":"2","key":"2062_CR71","first-page":"Fd01","volume":"11","author":"S Lahiry","year":"2017","unstructured":"Lahiry S, Choudhury S, Mukherjee A, Bhunya PK, Bala M. Polymyxin B-induced diffuse cutaneous hyperpigmentation. J Clin Diagn Res. 2017;11(2):Fd01-fd2.","journal-title":"J Clin Diagn Res"},{"key":"2062_CR72","doi-asserted-by":"publisher","first-page":"6461329","DOI":"10.1155\/2020\/6461329","volume":"2020","author":"X Wen","year":"2020","unstructured":"Wen X, Luo C, Lyu W. Polymyxin B-Induced Skin Hyperpigmentation. Case Rep Med. 2020;2020:6461329.","journal-title":"Case Rep Med"},{"issue":"2","key":"2062_CR73","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/j.1476-5381.1955.tb00085.x","volume":"10","author":"SR Bushby","year":"1955","unstructured":"Bushby SR, Green AF. The release or histamine by polymyxin B and polymyxin E. Br J Pharmacol Chemother. 1955;10(2):215\u20139.","journal-title":"Br J Pharmacol Chemother"},{"key":"2062_CR74","unstructured":"Dayavathi, Shah NM, Mangat GK, Dubey SG, Joshi VR. Redman syndrome. J Assoc Physicians. 1995;43(10):724."},{"issue":"11","key":"2062_CR75","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1136\/adc.62.11.1181","volume":"62","author":"J Salazar de Sousa","year":"1987","unstructured":"Salazar de Sousa J, Almeida V, Bray Pinheiro J. Red child syndrome. Arch Dis Child. 1987;62(11):1181.","journal-title":"Arch Dis Child"},{"issue":"6","key":"2062_CR76","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1007\/BF03259925","volume":"4","author":"MR Holdiness","year":"1989","unstructured":"Holdiness MR. A review of the Redman syndrome and rifampicin overdosage. Med Toxicol Adverse Drug Exp. 1989;4(6):444\u201351.","journal-title":"Med Toxicol Adverse Drug Exp"},{"issue":"5","key":"2062_CR77","first-page":"247","volume":"93","author":"LS Huff","year":"2014","unstructured":"Huff LS, Prado R, Pederson JF, Dunnick CA, Lucas LM. Chlorpromazine-induced skin pigmentation with corneal and lens opacities. Cutis. 2014;93(5):247\u201350.","journal-title":"Cutis"},{"issue":"8","key":"2062_CR78","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1111\/ijd.13085","volume":"55","author":"AM Molina-Ruiz","year":"2016","unstructured":"Molina-Ruiz AM, Pulpillo A, Molina-Ruiz RM, Sagrario T, Requena L. Chlorpromazine-induced severe skin pigmentation and corneal opacities in a patient with schizophrenia. Int J Dermatol. 2016;55(8):909\u201312.","journal-title":"Int J Dermatol"},{"issue":"8","key":"2062_CR79","first-page":"365","volume":"31","author":"ME Wolf","year":"1993","unstructured":"Wolf ME, Richer S, Berk MA, Mosnaim AD. Cutaneous and ocular changes associated with the use of chlorpromazine. Int J Clin Pharmacol Ther Toxicol. 1993;31(8):365\u20137.","journal-title":"Int J Clin Pharmacol Ther Toxicol"},{"issue":"4","key":"2062_CR80","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1111\/cup.13612","volume":"47","author":"T Calheiros","year":"2020","unstructured":"Calheiros T, de Almeida HL, Jorge VM, de Almeida AL, Motta L. Light and electron microscopy of chlorpromazine-induced hyperpigmentation. J Cutan Pathol. 2020;47(4):402\u20135.","journal-title":"J Cutan Pathol"},{"issue":"1","key":"2062_CR81","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.tiv.2014.10.016","volume":"29","author":"M Otreba","year":"2015","unstructured":"Otreba M, Wrze\u015bniok D, Beberok A, Rok J, Buszman E. Melanogenesis and antioxidant defense system in normal human melanocytes cultured in the presence of chlorpromazine. Toxicol In Vitro. 2015;29(1):221\u20137.","journal-title":"Toxicol In Vitro"},{"issue":"1","key":"2062_CR82","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/DAD.0b013e3182740122","volume":"36","author":"AM Molina-Ruiz","year":"2014","unstructured":"Molina-Ruiz AM, Cerroni L, Kutzner H, Requena L. Cutaneous deposits. Am J Dermatopathol. 2014;36(1):1\u201348.","journal-title":"Am J Dermatopathol"},{"issue":"2","key":"2062_CR83","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/j.1365-2230.1994.tb01145.x","volume":"19","author":"C Buckley","year":"1994","unstructured":"Buckley C, Thomas V, Lewin J, Harris D, Rustin MH. Stelazine-induced pigmentation. Clin Exp Dermatol. 1994;19(2):149\u201351.","journal-title":"Clin Exp Dermatol"},{"issue":"2","key":"2062_CR84","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1111\/phpp.12724","volume":"38","author":"E Boontaveeyuwat","year":"2022","unstructured":"Boontaveeyuwat E, Steyn M, Rickaby W, McFadden JP, Sarkany RPE, Fityan A. Tricyclic antidepressant-induced photosensitivity; a case report and systematic review. Photodermatol Photoimmunol Photomed. 2022;38(2):112\u201322.","journal-title":"Photodermatol Photoimmunol Photomed"},{"issue":"2","key":"2062_CR85","doi-asserted-by":"publisher","first-page":"13030\/qt3455571","DOI":"10.5070\/D3222030090","volume":"22","author":"DZ Eichenfield","year":"2016","unstructured":"Eichenfield DZ, Cohen PR. Amitriptyline-induced cutaneous hyperpigmentation: case report and review of psychotropic drug-associated mucocutaneous hyperpigmentation. Dermatol Online J. 2016;22(2):13030\/qt3455571b.","journal-title":"Dermatol Online J"},{"issue":"2 Pt 2","key":"2062_CR86","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/S0190-9622(99)70467-6","volume":"40","author":"MC Sicari","year":"1999","unstructured":"Sicari MC, Lebwohl M, Baral J, Wexler P, Gordon RE, Phelps RG. Photoinduced dermal pigmentation in patients taking tricyclic antidepressants: histology, electron microscopy, and energy dispersive spectroscopy. J Am Acad Dermatol. 1999;40(2 Pt 2):290\u20133.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"2062_CR87","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/j.1365-2133.1970.tb15731.x","volume":"83","author":"PJ Hare","year":"1970","unstructured":"Hare PJ. \u201cVisage mauve\u201d (? from imipramine). Br J Dermatol. 1970;83(3):420.","journal-title":"Br J Dermatol"},{"issue":"11","key":"2062_CR88","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1001\/archderm.1978.01640230069020","volume":"114","author":"RS Basler","year":"1978","unstructured":"Basler RS, Kohnen PW. Localized hemosiderosis as a sequela of acne. Arch Dermatol. 1978;114(11):1695\u20137.","journal-title":"Arch Dermatol"},{"issue":"4","key":"2062_CR89","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1001\/archderm.1993.01680250086012","volume":"129","author":"V Narurkar","year":"1993","unstructured":"Narurkar V, Smoller BR, Hu CH, Bauer EA. Desipramine-induced blue-gray photosensitive pigmentation. Arch Dermatol. 1993;129(4):474\u20136.","journal-title":"Arch Dermatol"},{"issue":"2","key":"2062_CR90","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/cup.14544","volume":"51","author":"B McKenna","year":"2024","unstructured":"McKenna B, Wold L, Noland MM, Schenck O. Novel hyperpigmentation pathophysiology following a prolonged course of imipramine therapy. J Cutan Pathol. 2024;51(2):105\u20137.","journal-title":"J Cutan Pathol"},{"issue":"1 Pt 1","key":"2062_CR91","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1067\/mjd.2000.105506","volume":"43","author":"DH Atkin","year":"2000","unstructured":"Atkin DH, Fitzpatrick RE. Laser treatment of imipramine-induced hyperpigmentation. J Am Acad Dermatol. 2000;43(1 Pt 1):77\u201380.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"2062_CR92","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1111\/j.1524-4725.2009.01082.x","volume":"35","author":"L Izikson","year":"2009","unstructured":"Izikson L, Anderson RR. Delayed darkening of imipramine-induced hyperpigmentation after treatment with a Q-switched Nd:YAG laser followed by a Q-switched ruby laser. Dermatol Surg. 2009;35(3):527\u20139.","journal-title":"Dermatol Surg"},{"issue":"2 Pt 1","key":"2062_CR93","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/S0190-9622(99)70182-9","volume":"40","author":"ME Ming","year":"1999","unstructured":"Ming ME, Bhawan J, Stefanato CM, McCalmont TH, Cohen LM. Imipramine-induced hyperpigmentation: four cases and a review of the literature. J Am Acad Dermatol. 1999;40(2 Pt 1):159\u201366.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"2062_CR94","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1111\/j.1368-5031.2004.00100.x","volume":"58","author":"M Nelson","year":"2004","unstructured":"Nelson M, Schiavone M. Emtricitabine (FTC) for the treatment of HIV infection. Int J Clin Pract. 2004;58(5):504\u201310.","journal-title":"Int J Clin Pract"},{"issue":"5","key":"2062_CR95","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1007\/s10156-011-0222-5","volume":"17","author":"T Shirasaka","year":"2011","unstructured":"Shirasaka T, Tadokoro T, Yamamoto Y, Fukutake K, Kato Y, Odawara T, et al. Investigation of emtricitabine-associated skin pigmentation and safety in HIV-1-infected Japanese patients. J Infect Chemother. 2011;17(5):602\u20138.","journal-title":"J Infect Chemother"},{"key":"2062_CR96","unstructured":"Mondou E. Incidence of skin discoloration across phase 3 clinical trials of emtricitabine (FTC) in adults. In: 15th international AIDS conference 2004 July 11\u201316; Bangkok, Thailand; 2004."},{"issue":"9","key":"2062_CR97","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1001\/archderm.1989.01670210123028","volume":"125","author":"C Bendick","year":"1989","unstructured":"Bendick C, Rasokat H, Steigleder GK. Azidothymidine-induced hyperpigmentation of skin and nails. Arch Dermatol. 1989;125(9):1285\u20136.","journal-title":"Arch Dermatol"},{"issue":"6","key":"2062_CR98","doi-asserted-by":"publisher","first-page":"801","DOI":"10.4103\/0253-7613.103306","volume":"44","author":"SM Chawre","year":"2012","unstructured":"Chawre SM, Pore SM, Nandeshwar MB, Masood NM. Zidovudine-induced nail pigmentation in a 12-year-old boy. Indian J Pharmacol. 2012;44(6):801\u20132.","journal-title":"Indian J Pharmacol."},{"issue":"6","key":"2062_CR99","first-page":"552","volume":"43","author":"CA Fisher","year":"1989","unstructured":"Fisher CA, McPoland PR. Azidothymidine-induced nail pigmentation. Cutis. 1989;43(6):552\u20134.","journal-title":"Cutis"},{"issue":"4","key":"2062_CR100","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0190-9622(08)81046-8","volume":"22","author":"M Grau-Massanes","year":"1990","unstructured":"Grau-Massanes M, Millan F, Febrer MI, Pujol C, Alegre VA, Salavert M, et al. Pigmented nail bands and mucocutaneous pigmentation in HIV-positive patients treated with zidovudine. J Am Acad Dermatol. 1990;22(4):687\u20138.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"2062_CR101","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/0002-9343(89)90348-3","volume":"86","author":"JA Merenich","year":"1989","unstructured":"Merenich JA, Hannon RN, Gentry RH, Harrison SM. Azidothymidine-induced hyperpigmentation mimicking primary adrenal insufficiency. Am J Med. 1989;86(4):469\u201370.","journal-title":"Am J Med"},{"issue":"1","key":"2062_CR102","doi-asserted-by":"publisher","first-page":"98","DOI":"10.4103\/2229-5178.126057","volume":"5","author":"SK Singh","year":"2014","unstructured":"Singh SK, Rai T. A case of zidovudine induced pigmentation on palms and soles. Indian Dermatol Online J. 2014;5(1):98\u20139.","journal-title":"Indian Dermatol Online J"},{"issue":"1","key":"2062_CR103","first-page":"38","volume":"7","author":"VR Tandon","year":"2016","unstructured":"Tandon VR, Sadiq S, Khajuria V, Mahajan A, Sharma S, Gillani Z. Zidovudine-induced nail hyper-pigmentation in 45-year-old women prescribed for HIV\/tuberculosis co-infection. J Midlife Health. 2016;7(1):38\u201340.","journal-title":"J Midlife Health."},{"issue":"3","key":"2062_CR104","doi-asserted-by":"publisher","first-page":"223","DOI":"10.4103\/ijp.IJP_304_16","volume":"49","author":"S Mukherjee","year":"2017","unstructured":"Mukherjee S, Era N, Saha B, Tripathi SK. Adverse drug reaction monitoring in patients on antiretroviral therapy in a tertiary care hospital in Eastern India. Indian J Pharmacol. 2017;49(3):223\u20138.","journal-title":"Indian J Pharmacol."},{"issue":"3","key":"2062_CR105","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/S0190-9622(85)70079-5","volume":"12","author":"A Alinovi","year":"1985","unstructured":"Alinovi A, Reverberi C, Melissari M, Gabrielli M. Cutaneous hyperpigmentation induced by amiodarone hydrochloride. J Am Acad Dermatol. 1985;12(3):563\u20136.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"2062_CR106","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1001\/archdermatol.2007.25","volume":"144","author":"A Ammoury","year":"2008","unstructured":"Ammoury A, Michaud S, Paul C, Prost-Squarcioni C, Alvarez F, Lamant L, et al. Photodistribution of blue-gray hyperpigmentation after amiodarone treatment: molecular characterization of amiodarone in the skin. Arch Dermatol. 2008;144(1):92\u20136.","journal-title":"Arch Dermatol"},{"issue":"11","key":"2062_CR107","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1001\/archderm.1983.01650350042012","volume":"119","author":"JW Trimble","year":"1983","unstructured":"Trimble JW, Mendelson DS, Fetter BF, Ingram P, Gallagher JJ, Shelburne JD. Cutaneous pigmentation secondary to amiodarone therapy. Arch Dermatol. 1983;119(11):914\u20138.","journal-title":"Arch Dermatol"},{"issue":"11","key":"2062_CR108","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1001\/jama.298.11.1312","volume":"298","author":"P Vassallo","year":"2007","unstructured":"Vassallo P, Trohman RG. Prescribing amiodarone: an evidence-based review of clinical indications. JAMA. 2007;298(11):1312\u201322.","journal-title":"JAMA"},{"issue":"10","key":"2062_CR109","first-page":"1205","volume":"112","author":"C Delage","year":"1975","unstructured":"Delage C, Lagac\u00e9 R, Huard J. Pseudocyanotic pigmentation of the skin induced by amiodarone: a light and electron microscopic study. Can Med Assoc J. 1975;112(10):1205\u20138.","journal-title":"Can Med Assoc J"},{"issue":"2","key":"2062_CR110","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1111\/1523-1747.ep12277571","volume":"93","author":"K Rappersberger","year":"1989","unstructured":"Rappersberger K, H\u00f6nigsmann H, Ortel B, Tanew A, Konrad K, Wolff K. Photosensitivity and hyperpigmentation in amiodarone-treated patients: incidence, time course, and recovery. J Invest Dermatol. 1989;93(2):201\u20139.","journal-title":"J Invest Dermatol"},{"issue":"7","key":"2062_CR111","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1002\/clc.4960190713","volume":"19","author":"NG Kounis","year":"1996","unstructured":"Kounis NG, Frangides C, Papadaki PJ, Zavras GM, Goudevenos J. Dose-dependent appearance and disappearance of amiodarone-induced skin pigmentation. Clin Cardiol. 1996;19(7):592\u20134.","journal-title":"Clin Cardiol"},{"issue":"11","key":"2062_CR112","first-page":"1316","volume":"10","author":"EF Bernstein","year":"2011","unstructured":"Bernstein EF. Q-switched laser treatment of amiodarone pigmentation. J Drugs Dermatol. 2011;10(11):1316\u20139.","journal-title":"J Drugs Dermatol"},{"issue":"3","key":"2062_CR113","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1001\/archderm.135.3.251","volume":"135","author":"S Karrer","year":"1999","unstructured":"Karrer S, Hohenleutner U, Szeimies RM, Landthaler M. Amiodarone-induced pigmentation resolves after treatment with the Q-switched ruby laser. Arch Dermatol. 1999;135(3):251\u20133.","journal-title":"Arch Dermatol"},{"issue":"5","key":"2062_CR114","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1001\/archderm.1984.01650410088022","volume":"120","author":"RA Miller","year":"1984","unstructured":"Miller RA, McDonald AT. Dermal lipofuscinosis associated with amiodarone therapy. Report of a case. Arch Dermatol. 1984;120(5):646\u20139.","journal-title":"Arch Dermatol"},{"issue":"10","key":"2062_CR115","first-page":"976","volume":"55","author":"S Zgazarova","year":"2009","unstructured":"Zgazarova S, Jedlickova H, Vasku V. Skin adverse effects of amiodarone [in Czech]. Vnitr Lek. 2009;55(10):976\u201380.","journal-title":"Vnitr Lek"},{"issue":"5","key":"2062_CR116","doi-asserted-by":"publisher","first-page":"10","DOI":"10.5070\/D33C97J4Z5","volume":"9","author":"M Boyer","year":"2003","unstructured":"Boyer M, Katta R, Markus R. Diltiazem-induced photodistributed hyperpigmentation. Dermatol Online J. 2003;9(5):10.","journal-title":"Dermatol Online J"},{"issue":"7","key":"2062_CR117","doi-asserted-by":"publisher","first-page":"14","DOI":"10.5070\/D34580R7RS","volume":"17","author":"A Jaka","year":"2011","unstructured":"Jaka A, L\u00f3pez-Pesta\u00f1a A, Tuneu A, Lobo C, L\u00f3pez-N\u00fa\u00f1ez M, Ormaechea N. Letter: Photodistributed reticulated hyperpigmentation related to diltiazem. Dermatol Online J. 2011;17(7):14.","journal-title":"Dermatol Online J"},{"issue":"4","key":"2062_CR118","first-page":"239","volume":"73","author":"T Kuykendall-Ivy","year":"2004","unstructured":"Kuykendall-Ivy T, Collier SL, Johnson SM. Diltiazem-induced hyperpigmentation. Cutis. 2004;73(4):239\u201340.","journal-title":"Cutis"},{"issue":"8","key":"2062_CR119","doi-asserted-by":"publisher","first-page":"e390","DOI":"10.1111\/1346-8138.15960","volume":"48","author":"N Oiso","year":"2021","unstructured":"Oiso N, Yanagihara S, Nakagawa K, Kawada A. Diltiazem-associated photodistributed hyperpigmentation with abundant immature melanosome leakage into the dermis. J Dermatol. 2021;48(8):e390\u20132.","journal-title":"J Dermatol"},{"issue":"2","key":"2062_CR120","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1001\/archderm.142.2.206","volume":"142","author":"RN Saladi","year":"2006","unstructured":"Saladi RN, Cohen SR, Phelps RG, Persaud AN, Rudikoff D. Diltiazem induces severe photodistributed hyperpigmentation: case series, histoimmunopathology, management, and review of the literature. Arch Dermatol. 2006;142(2):206\u201310.","journal-title":"Arch Dermatol"},{"issue":"1","key":"2062_CR121","first-page":"45","volume":"93","author":"JD Siegel","year":"2020","unstructured":"Siegel JD, Ko CJ. Diltiazem-associated photodistributed hyperpigmentation. Yale J Biol Med. 2020;93(1):45\u20137.","journal-title":"Yale J Biol Med"},{"issue":"9","key":"2062_CR122","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1111\/j.1346-8138.2010.00858.x","volume":"37","author":"Y Kubo","year":"2010","unstructured":"Kubo Y, Fukumoto D, Ishigami T, Hida Y, Arase S. Diltiazem-associated photodistributed hyperpigmentation: report of two Japanese cases and published work review. J Dermatol. 2010;37(9):807\u201311.","journal-title":"J Dermatol"},{"issue":"2","key":"2062_CR123","first-page":"179","volume":"137","author":"L Scherschun","year":"2001","unstructured":"Scherschun L, Lee MW, Lim HW. Diltiazem-associated photodistributed hyperpigmentation: a review of 4 cases. Arch Dermatol. 2001;137(2):179\u201382.","journal-title":"Arch Dermatol"},{"issue":"4","key":"2062_CR124","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/jch.12665","volume":"18","author":"R Gim\u00e9nez-Garc\u00eda","year":"2016","unstructured":"Gim\u00e9nez-Garc\u00eda R. Hyperpigmentation induced by combination therapy with telmisartan-hydrochlorothiazide. J Clin Hypertens (Greenwich). 2016;18(4):361\u20132.","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"6","key":"2062_CR125","doi-asserted-by":"publisher","first-page":"714","DOI":"10.4103\/0378-6323.72459","volume":"76","author":"R Rao","year":"2010","unstructured":"Rao R, Balachandran C. Serpentine supravenous pigmentation. A rare vasculo-cutaneous effect induced by systemic 5-fluorouracil. Indian J Dermatol Venereol Leprol. 2010;76(6):714\u20135.","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"3","key":"2062_CR126","doi-asserted-by":"publisher","first-page":"e66","DOI":"10.1097\/DSS.0000000000002879","volume":"47","author":"T Searle","year":"2021","unstructured":"Searle T, Al-Niaimi F, Ali FR. 5-fluorouracil in dermatology: the diverse uses beyond malignant and premalignant skin disease. Dermatol Surg. 2021;47(3):e66\u201370.","journal-title":"Dermatol Surg"},{"issue":"5 Pt 2","key":"2062_CR127","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0190-9622(98)70361-5","volume":"39","author":"RM Pujol","year":"1998","unstructured":"Pujol RM, Rocamora V, Lopez-Pousa A, Taberner R, Alomar A. Persistent supravenous erythematous eruption: a rare local complication of intravenous 5-fluorouracil therapy. J Am Acad Dermatol. 1998;39(5 Pt 2):839\u201342.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"2062_CR128","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/j.1365-4362.1995.tb01579.x","volume":"34","author":"BJ Allen","year":"1995","unstructured":"Allen BJ, Parker D, Wright AL. Reticulate pigmentation due to 5-fluorouracil. Int J Dermatol. 1995;34(3):219\u201320.","journal-title":"Int J Dermatol"},{"key":"2062_CR129","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1111\/j.1365-2133.1962.tb13497.x","volume":"74","author":"G Falkson","year":"1962","unstructured":"Falkson G, Schulz EJ. Skin changes in patients treated with 5-fluorouracil. Br J Dermatol. 1962;74:229\u201336.","journal-title":"Br J Dermatol"},{"issue":"2","key":"2062_CR130","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1001\/jama.1976.03270020012002","volume":"236","author":"WJ Hrushesky","year":"1976","unstructured":"Hrushesky WJ. Letter: Serpentine supravenous fluorouracil hyperpigmentation. JAMA. 1976;236(2):138.","journal-title":"JAMA"},{"issue":"7","key":"2062_CR131","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1248\/bpb.b23-00108","volume":"46","author":"A Fujito","year":"2023","unstructured":"Fujito A, Hiramoto K, Imai M, Tanaka S, Ooi K. ACTH\/cAMP-mediated skin pigmentation caused by 5-fluorouracil administration. Biol Pharm Bull. 2023;46(7):955\u201363.","journal-title":"Biol Pharm Bull"},{"issue":"1","key":"2062_CR132","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1248\/bpb.b23-00584","volume":"47","author":"A Fujito","year":"2024","unstructured":"Fujito A, Tanaka S, Hiramoto K, Ma N, Ooi K. The mechanism of 5-fluorouracil-induced hyperpigmentation in HRM-2 hairless mice: focus on the increase of blood vessels. Biol Pharm Bull. 2024;47(1):311\u20137.","journal-title":"Biol Pharm Bull"},{"issue":"1","key":"2062_CR133","doi-asserted-by":"publisher","DOI":"10.1213\/XAA.0000000000001551","volume":"16","author":"J Heninger","year":"2022","unstructured":"Heninger J, Cheon E, Green J, Hajduk J, Benzon H. Intralesional bleomycin injection and skin hyperpigmentation: a case series of a single-center experience with a standardized skin-protective protocol. A A Pract. 2022;16(1): e01551.","journal-title":"A A Pract."},{"key":"2062_CR134","doi-asserted-by":"publisher","first-page":"bcr2013009745","DOI":"10.1136\/bcr-2013-009745","volume":"2013","author":"C Resende","year":"2013","unstructured":"Resende C, Araujo C, Gomes J, Brito C. Bleomycin-induced flagellate hyperpigmentation. BMJ Case Rep. 2013;2013:bcr2013009745.","journal-title":"BMJ Case Rep"},{"issue":"4","key":"2062_CR135","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1001\/archderm.1973.01620190029007","volume":"107","author":"IS Cohen","year":"1973","unstructured":"Cohen IS, Mosher MB, O\u2019Keefe EJ, Klaus SN, De Conti RC. Cutaneous toxicity of bleomycin therapy. Arch Dermatol. 1973;107(4):553\u20135.","journal-title":"Arch Dermatol"},{"issue":"1","key":"2062_CR136","doi-asserted-by":"publisher","first-page":"68","DOI":"10.2165\/11537080-000000000-00000","volume":"12","author":"M Ziemer","year":"2011","unstructured":"Ziemer M, Goetze S, Juhasz K, Elsner P. Flagellate dermatitis as a bleomycin-specific adverse effect of cytostatic therapy: a clinical-histopathologic correlation. Am J Clin Dermatol. 2011;12(1):68\u201376.","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"2062_CR137","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/S0190-9622(85)70190-9","volume":"13","author":"AC Fernandez-Obregon","year":"1985","unstructured":"Fernandez-Obregon AC, Hogan KP, Bibro MK. Flagellate pigmentation from intrapleural bleomycin. A light microscopy and electron microscopy study. J Am Acad Dermatol. 1985;13(3):464\u20138.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"2062_CR138","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1159\/000248004","volume":"180","author":"P Cortina","year":"1990","unstructured":"Cortina P, Garrido JA, Tomas JF, Unamuno P, Armijo M. \u201cFlagellate\u201d erythema from bleomycin. With histopathological findings suggestive of inflammatory oncotaxis. Dermatologica. 1990;180(2):106\u20139.","journal-title":"Dermatologica"},{"issue":"2","key":"2062_CR139","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1046\/j.1365-4362.1999.00344.x","volume":"38","author":"NG Rubeiz","year":"1999","unstructured":"Rubeiz NG, Salem Z, Dibbs R, Kibbi AG. Bleomycin-induced urticarial flagellate drug hypersensitivity reaction. Int J Dermatol. 1999;38(2):140\u20131.","journal-title":"Int J Dermatol"},{"issue":"1","key":"2062_CR140","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/pde.14869","volume":"39","author":"KP Davis","year":"2022","unstructured":"Davis KP, Gaffey MM, Kompelli AR, Richter GT. Cutaneous hyperpigmentation following bleomycin sclerotherapy for vascular malformations. Pediatr Dermatol. 2022;39(1):103\u20136.","journal-title":"Pediatr Dermatol"},{"issue":"9","key":"2062_CR141","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1016\/j.jvir.2018.10.007","volume":"30","author":"HC Milbar","year":"2019","unstructured":"Milbar HC, Jeon H, Ward MA, Mitchell SE, Weiss CR, Cohen BA. Hyperpigmentation after foamed bleomycin sclerotherapy for vascular malformations. J Vasc Interv Radiol. 2019;30(9):1438\u201342.","journal-title":"J Vasc Interv Radiol"},{"issue":"6","key":"2062_CR142","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1111\/j.1346-8138.1980.tb01993.x","volume":"7","author":"BA Adam","year":"1980","unstructured":"Adam BA, Ismail R, Sivanesan S. Busulfan hyperpigmentation: light and electron microscopic studies. J Dermatol. 1980;7(6):405\u201311.","journal-title":"J Dermatol"},{"issue":"5489","key":"2062_CR143","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1136\/bmj.1.5489.736-d","volume":"1","author":"JG Sprunt","year":"1966","unstructured":"Sprunt JG, Rizza CR. Pigmentation and busulphan therapy. Br Med J. 1966;1(5489):736\u20137.","journal-title":"Br Med J"},{"issue":"5485","key":"2062_CR144","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1136\/bmj.1.5485.463","volume":"1","author":"BP Harrold","year":"1966","unstructured":"Harrold BP. Syndrome resembling Addison\u2019s disease following prolonged treatment with busulphan. Br Med J. 1966;1(5485):463\u20134.","journal-title":"Br Med J"},{"issue":"S1","key":"2062_CR145","first-page":"38","volume":"87","author":"JA Garcia-Lozano","year":"2019","unstructured":"Garcia-Lozano JA, Ocampo-Candiani J, Gonzalez-Ramirez RA. Eruptive palmoplantar lesions induced by capecitabine: report of a case evaluated with dermoscopy. Cir Cir. 2019;87(S1):38\u201342.","journal-title":"Cir Cir"},{"issue":"4","key":"2062_CR146","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.21873\/invivo.13280","volume":"37","author":"M Yamada","year":"2023","unstructured":"Yamada M, Iijima Y, Seo M, Hino S, Sano M, Sakagami H, et al. Cancer chemotherapy-associated pigmentation of the oral mucosa. In Vivo. 2023;37(4):1880\u20135.","journal-title":"In Vivo"},{"issue":"3","key":"2062_CR147","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.abd.2022.05.004","volume":"98","author":"A Nascimento","year":"2023","unstructured":"Nascimento A, Porto DM, Vidal AKL. Capecitabine-induced oral mucosal hyperpigmentation associated with hand-foot syndrome - a literature review. An Bras Dermatol. 2023;98(3):302\u20139.","journal-title":"An Bras Dermatol"},{"issue":"10","key":"2062_CR148","doi-asserted-by":"publisher","first-page":"11","DOI":"10.5070\/D39207D9JR","volume":"15","author":"T Paravar","year":"2009","unstructured":"Paravar T, Hymes SR. Longitudinal melanonychia induced by capecitabine. Dermatol Online J. 2009;15(10):11.","journal-title":"Dermatol Online J"},{"issue":"5","key":"2062_CR149","doi-asserted-by":"publisher","first-page":"326","DOI":"10.4103\/0253-7613.70401","volume":"42","author":"B Vasudevan","year":"2010","unstructured":"Vasudevan B. An unusual case of capecitabine hyperpigmentation: is hyperpigmentation a part of hand-foot syndrome or a separate entity? Indian J Pharmacol. 2010;42(5):326\u20138.","journal-title":"Indian J Pharmacol."},{"issue":"3","key":"2062_CR150","doi-asserted-by":"publisher","first-page":"373","DOI":"10.2340\/00015555-2551","volume":"97","author":"KM MacArthur","year":"2017","unstructured":"MacArthur KM, Jariwala N, Kim EJ, Rook AH. Topical carmustine as monotherapy or as multimodality therapy for folliculotropic mycosis fungoides. Acta Derm Venereol. 2017;97(3):373\u20134.","journal-title":"Acta Derm Venereol"},{"issue":"6","key":"2062_CR151","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1684\/ejd.2017.3180","volume":"27","author":"I Hernandez-Aragues","year":"2017","unstructured":"Hernandez-Aragues I, Baniandres-Rodriguez O, Vilas-Boas PT, Conde-Montero E, Suarez-Fernandez R. Cutaneous drug reactions: chemotherapy-induced hyperpigmentation. Eur J Dermatol. 2017;27(6):679\u201380.","journal-title":"Eur J Dermatol"},{"issue":"6","key":"2062_CR152","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1517\/14740338.3.6.579","volume":"3","author":"B Guillot","year":"2004","unstructured":"Guillot B, Bessis D, Dereure O. Mucocutaneous side effects of antineoplastic chemotherapy. Expert Opin Drug Saf. 2004;3(6):579\u201387.","journal-title":"Expert Opin Drug Saf"},{"issue":"1","key":"2062_CR153","first-page":"OD04","volume":"11","author":"VB Prajapati","year":"2017","unstructured":"Prajapati VB, Madhyastha S, Acharya R, Gopalaswamy V, Doddamani A. Cyclophosphamide and doxorubicin induced melanonychia: a case report. J Clin Diagn Res. 2017;11(1):OD04\u20135.","journal-title":"J Clin Diagn Res"},{"issue":"9","key":"2062_CR154","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.1002\/1097-0142(19930501)71:9<2873::AID-CNCR2820710931>3.0.CO;2-6","volume":"71","author":"ME Teresi","year":"1993","unstructured":"Teresi ME, Murry DJ, Cornelius AS. Ifosfamide-induced hyperpigmentation. Cancer. 1993;71(9):2873\u20135.","journal-title":"Cancer"},{"issue":"6","key":"2062_CR155","doi-asserted-by":"publisher","first-page":"405","DOI":"10.4103\/ijp.ijp_53_23","volume":"55","author":"SS Morabad","year":"2023","unstructured":"Morabad SS, Khan ZU, Gad R, Kallur N, Madhabhavi IV, Shalavadi MH, et al. Tongue and teeth hyperpigmentation in etoposide, prednisolone, vincristine, and cyclophosphamide regimen in the treatment of cutaneous lymphoma. Indian J Pharmacol. 2023;55(6):405\u20137.","journal-title":"Indian J Pharmacol."},{"issue":"3","key":"2062_CR156","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1002\/(SICI)1096-911X(199709)29:3<226::AID-MPO13>3.0.CO;2-B","volume":"29","author":"MJ Coppes","year":"1997","unstructured":"Coppes MJ, Jorgenson K, Arlette JP. Cutaneous toxicity following the administration of dactinomycin. Med Pediatr Oncol. 1997;29(3):226\u20137.","journal-title":"Med Pediatr Oncol"},{"issue":"5","key":"2062_CR157","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1002\/mpo.2950240512","volume":"24","author":"VS Kanwar","year":"1995","unstructured":"Kanwar VS, Gajjar A, Ribeiro RC, Bowman L, Parham DM, Jenkins JJ 3rd. Unusual cutaneous toxicity following treatment with dactinomycin: a report of two cases. Med Pediatr Oncol. 1995;24(5):329\u201333.","journal-title":"Med Pediatr Oncol"},{"issue":"5","key":"2062_CR158","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1111\/j.1445-2197.1982.tb06046.x","volume":"52","author":"TT Alagaratnam","year":"1982","unstructured":"Alagaratnam TT, Choi TK, Ong GB. Doxorubicin and hyperpigmentation. Aust N Z J Surg. 1982;52(5):531\u20133.","journal-title":"Aust N Z J Surg"},{"issue":"900","key":"2062_CR159","first-page":"517","volume":"103","author":"CF Curran","year":"1990","unstructured":"Curran CF. Doxorubicin-associated hyperpigmentation. N Z Med J. 1990;103(900):517.","journal-title":"N Z Med J"},{"issue":"10","key":"2062_CR160","doi-asserted-by":"publisher","first-page":"18","DOI":"10.5070\/D365M8X79P","volume":"14","author":"NR Abbasi","year":"2008","unstructured":"Abbasi NR, Wang N. Doxorubicin-induced hyperpigmentation. Dermatol Online J. 2008;14(10):18.","journal-title":"Dermatol Online J"},{"issue":"3","key":"2062_CR161","first-page":"499","volume":"61","author":"D Morris","year":"1977","unstructured":"Morris D, Aisner J, Wiernik PH. Horizontal pigmented banding of the nails in association with adriamycin chemotherapy. Cancer Treat Rep. 1977;61(3):499\u2013501.","journal-title":"Cancer Treat Rep"},{"issue":"7920","key":"2062_CR162","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1016\/S0140-6736(75)92341-7","volume":"305","author":"TJ Priestman","year":"1975","unstructured":"Priestman TJ, James KW. Letter: Adriamycin and longitudinal pigmented banding of fingernails. Lancet. 1975;305(7920):1337\u20138.","journal-title":"Lancet"},{"issue":"5","key":"2062_CR163","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1111\/j.1365-2141.2010.08358.x","volume":"151","author":"RR Pol","year":"2010","unstructured":"Pol RR, Wright A, Hill A. Daunorubicin-induced hyperpigmentation. Br J Haematol. 2010;151(5):414.","journal-title":"Br J Haematol"},{"issue":"22","key":"2062_CR164","doi-asserted-by":"publisher","first-page":"4646","DOI":"10.1200\/JCO.2004.02.168","volume":"22","author":"GC Chang","year":"2004","unstructured":"Chang GC, Yang TY, Chen KC, Yin MC, Wang RC, Lin YC. Complications of therapy in cancer patients: Case 1. Paronychia and skin hyperpigmentation induced by gefitinib in advanced non-small-cell lung cancer. J Clin Oncol. 2004;22(22):4646\u20138.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2062_CR165","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1159\/000503758","volume":"6","author":"T Cosio","year":"2020","unstructured":"Cosio T, Mazzilli S, Bianchi L, Campione E. The dark side of gefitinib: reflectance confocal microscopy applied to hair hyperpigmentation. Skin Appendage Disord. 2020;6(1):44\u20137.","journal-title":"Skin Appendage Disord."},{"issue":"1","key":"2062_CR166","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1046\/j.0307-6938.2001.00947.x","volume":"27","author":"B Kumar","year":"2002","unstructured":"Kumar B, Saraswat A, Kaur I. Mucocutaneous adverse effects of hydroxyurea: a prospective study of 30 psoriasis patients. Clin Exp Dermatol. 2002;27(1):8\u201313.","journal-title":"Clin Exp Dermatol"},{"issue":"3","key":"2062_CR167","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2022-249123","volume":"15","author":"K Divyashree","year":"2022","unstructured":"Divyashree K, Gupta R, Chandana VS, Pannu AK. Hydroxyurea-induced lunular hyperpigmentation. BMJ Case Rep. 2022;15(3): e249123.","journal-title":"BMJ Case Rep"},{"key":"2062_CR168","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jdcr.2023.09.027","volume":"42","author":"MG Buontempo","year":"2023","unstructured":"Buontempo MG, Chaudhry ZS, Raval RS, Mourtzanakis K, Ramachandran V, Shapiro J, et al. Hydroxyurea-induced melanonychia. JAAD Case Rep. 2023;42:91\u20134.","journal-title":"JAAD Case Rep."},{"issue":"12","key":"2062_CR169","volume":"11","author":"E Neculiseanu","year":"2019","unstructured":"Neculiseanu E, Harewood J, Sidhu G. Hydroxyurea-induced tongue hypermelanosis and transverse melanonychia. Cureus. 2019;11(12): e6311.","journal-title":"Cureus."},{"issue":"1","key":"2062_CR170","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1067\/mjd.2002.120910","volume":"47","author":"N Aste","year":"2002","unstructured":"Aste N, Fumo G, Contu F, Aste N, Biggio P. Nail pigmentation caused by hydroxyurea: report of 9 cases. J Am Acad Dermatol. 2002;47(1):146\u20137.","journal-title":"J Am Acad Dermatol"},{"key":"2062_CR171","doi-asserted-by":"publisher","first-page":"bcr2016218644","DOI":"10.1136\/bcr-2016-218644","volume":"2017","author":"AL Nguyen","year":"2017","unstructured":"Nguyen AL, Korver JE, Theunissen CC. Longitudinal melanonychia on multiple nails induced by hydroxyurea. BMJ Case Rep. 2017;2017:bcr2016218644.","journal-title":"BMJ Case Rep"},{"issue":"10","key":"2062_CR172","doi-asserted-by":"publisher","first-page":"13030\/qt6q51c0p","DOI":"10.5070\/D32510045820","volume":"25","author":"KP Lee","year":"2019","unstructured":"Lee KP, Vangipuram RK, Klimas NK, Sanyal S, Koshelev MV. Hydroxyurea-induced hyperpigmentation with iron deposition. Dermatol Online J. 2019;25(10):13030\/qt6q51c0p9.","journal-title":"Dermatol Online J"},{"issue":"6 Pt 1","key":"2062_CR173","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1016\/S0190-9622(08)80119-3","volume":"24","author":"S Vomvouras","year":"1991","unstructured":"Vomvouras S, Pakula AS, Shaw JM. Multiple pigmented nail bands during hydroxyurea therapy: an uncommon finding. J Am Acad Dermatol. 1991;24(6 Pt 1):1016\u20137.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"2062_CR174","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S0733-8635(18)30888-X","volume":"3","author":"CR Daniel 3rd","year":"1985","unstructured":"Daniel CR 3rd, Scher RK. Nail changes caused by systemic drugs or ingestants. Dermatol Clin. 1985;3(3):491\u2013500.","journal-title":"Dermatol Clin"},{"issue":"10","key":"2062_CR175","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1001\/archderm.1977.01640100065010","volume":"113","author":"NM Price","year":"1977","unstructured":"Price NM. Topical mechlorethamine. Cutaneous changes in patients with mycosis fungoides after its administration. Arch Dermatol. 1977;113(10):1387\u20139.","journal-title":"Arch Dermatol"},{"issue":"3","key":"2062_CR176","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1001\/archderm.1966.01600270015003","volume":"94","author":"P Frost","year":"1966","unstructured":"Frost P, DeVita VT. Pigmentation due to a new antitumor agent. Effects of topical application of BCNU [1,3-bis(2-chloroethyl)-1-nitrosourea]. Arch Dermatol. 1966;94(3):265\u20138.","journal-title":"Arch Dermatol"},{"issue":"5","key":"2062_CR177","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1001\/archdermatol.2011.2797","volume":"148","author":"N Apisarnthanarax","year":"2012","unstructured":"Apisarnthanarax N, Wood GS, Stevens SR, Carlson S, Chan DV, Liu L, et al. Phase I clinical trial of O6-benzylguanine and topical carmustine in the treatment of cutaneous T-cell lymphoma, mycosis fungoides type. Arch Dermatol. 2012;148(5):613\u201320.","journal-title":"Arch Dermatol"},{"issue":"6","key":"2062_CR178","first-page":"751","volume":"17","author":"E Toussirot","year":"1999","unstructured":"Toussirot E, Wendling D. Methotrexate-induced hyperpigmentation in a rheumatoid arthritis patient. Clin Exp Rheumatol. 1999;17(6):751.","journal-title":"Clin Exp Rheumatol"},{"issue":"7","key":"2062_CR179","doi-asserted-by":"publisher","first-page":"e287","DOI":"10.1097\/RHU.0000000000001428","volume":"27","author":"PK Panda","year":"2021","unstructured":"Panda PK, Sharawat IK, Yadav R. Methotrexate-induced hyperpigmentation over sun-exposed area. J Clin Rheumatol. 2021;27(7):e287\u20138.","journal-title":"J Clin Rheumatol"},{"issue":"9","key":"2062_CR180","volume":"14","author":"KM Hamed","year":"2022","unstructured":"Hamed KM, Dighriri IM, Baomar AF, Alharthy BT, Alenazi FE, Alali GH, et al. Overview of methotrexate toxicity: a comprehensive literature review. Cureus. 2022;14(9): e29518.","journal-title":"Cureus."},{"key":"2062_CR181","first-page":"254","volume":"53","author":"M Lee","year":"2015","unstructured":"Lee M, Lee JH, Lee JY, Park YM. Hyperpigmentation probably induced by methotrexate in a patient with rheumatoid arthritis. Korean J Dermatol. 2015;53:254\u20135.","journal-title":"Korean J Dermatol."},{"issue":"1","key":"2062_CR182","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/fcp.12943","volume":"38","author":"P Montero","year":"2024","unstructured":"Montero P, Sanz C, Perez-Fidalgo JA, Perez-Leal M, Milara J, Cortijo J. Paclitaxel alters melanogenesis and causes pigmentation in the skin of gynecological cancer patients. Fundam Clin Pharmacol. 2024;38(1):183\u201391.","journal-title":"Fundam Clin Pharmacol"},{"issue":"4","key":"2062_CR183","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1159\/000439047","volume":"231","author":"M Masson Regnault","year":"2015","unstructured":"Masson Regnault M, Gadaud N, Boulinguez S, Tournier E, Lamant L, Gladieff L, et al. Chemotherapy-related reticulate hyperpigmentation: a case series and review of the literature. Dermatology. 2015;231(4):312\u20138.","journal-title":"Dermatology"},{"issue":"1","key":"2062_CR184","first-page":"E12","volume":"95","author":"MK Garshick","year":"2015","unstructured":"Garshick MK, Myskowski P, Scher R. Paclitaxel-associated melanonychia. Cutis. 2015;95(1):E12\u20134.","journal-title":"Cutis"},{"issue":"12","key":"2062_CR185","doi-asserted-by":"publisher","first-page":"390","DOI":"10.12998\/wjcc.v4.i12.390","volume":"4","author":"PR Cohen","year":"2016","unstructured":"Cohen PR. Paclitaxel-associated reticulate hyperpigmentation: report and review of chemotherapy-induced reticulate hyperpigmentation. World J Clin Cases. 2016;4(12):390\u2013400.","journal-title":"World J Clin Cases."},{"issue":"5","key":"2062_CR186","first-page":"1753","volume":"31","author":"D Schallier","year":"2011","unstructured":"Schallier D, Decoster L, de Greve J. Pemetrexed-induced hyperpigmentation of the skin. Anticancer Res. 2011;31(5):1753\u20135.","journal-title":"Anticancer Res"},{"issue":"2","key":"2062_CR187","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/j.1540-9740.2007.05720.x","volume":"6","author":"CA Dasanu","year":"2007","unstructured":"Dasanu CA, Wiernik PH, Vaillant J, Alexandrescu DT. A complex pattern of melanonychia and onycholysis after treatment with pemetrexed for lung cancer. Skinmed. 2007;6(2):95\u20136.","journal-title":"Skinmed."},{"issue":"2","key":"2062_CR188","doi-asserted-by":"publisher","DOI":"10.4081\/dr.2011.e30","volume":"3","author":"V Teixeira","year":"2011","unstructured":"Teixeira V, Vieira R, Figueiredo A. Tegafur-induced acral hyperpigmentation. Dermatol Rep. 2011;3(2): e30.","journal-title":"Dermatol Rep."},{"issue":"3","key":"2062_CR189","first-page":"205","volume":"48","author":"E Llistosella","year":"1991","unstructured":"Llistosella E, Codina A, Alvarez R, Pujol RM, de Moragas JM. Tegafur-induced acral hyperpigmentation. Cutis. 1991;48(3):205\u20137.","journal-title":"Cutis"},{"issue":"2","key":"2062_CR190","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s10384-010-0917-7","volume":"55","author":"H Kobashi","year":"2011","unstructured":"Kobashi H, Kamiya K, Shimizu K. A case of corneal epithelial lesion and keratoconjunctival pigmentation due to anticancer drug S-1. Jpn J Ophthalmol. 2011;55(2):163\u20135.","journal-title":"Jpn J Ophthalmol"},{"issue":"3","key":"2062_CR191","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1111\/j.1365-2133.2004.06149.x","volume":"151","author":"S Fukushima","year":"2004","unstructured":"Fukushima S, Hatta N. Atypical moles in a patient undergoing chemotherapy with oral 5-fluorouracil prodrug. Br J Dermatol. 2004;151(3):698\u2013700.","journal-title":"Br J Dermatol"},{"issue":"5","key":"2062_CR192","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1111\/cup.12298","volume":"41","author":"M Llamas-Velasco","year":"2014","unstructured":"Llamas-Velasco M, Fraga J, Kutzner H, Steegmann JL, Garcia-Diez A, Requena L. Hypopigmented macules secondary to imatinib for the treatment of chronic myeloid leukemia: a histopathologic and immunohistochemical study. J Cutan Pathol. 2014;41(5):417\u201326.","journal-title":"J Cutan Pathol"},{"issue":"12","key":"2062_CR193","doi-asserted-by":"publisher","first-page":"4371","DOI":"10.1007\/s00784-019-02886-0","volume":"23","author":"SR Oliveira","year":"2019","unstructured":"Oliveira SR, de Azevedo Branco LG, Rocha AL, Travassos DV, Magalhaes GHR, Fonseca FP, et al. Association of oral mucosa hyperpigmentation with imatinib mesylate use: a cross-sectional study and a systematic literature review. Clin Oral Investig. 2019;23(12):4371\u201382.","journal-title":"Clin Oral Investig"},{"issue":"3","key":"2062_CR194","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1097\/MPH.0b013e318033a76c","volume":"29","author":"N Singh","year":"2007","unstructured":"Singh N, Bakhshi S. Imatinib-induced dental hyperpigmentation in childhood chronic myeloid leukemia. J Pediatr Hematol Oncol. 2007;29(3):208\u20139.","journal-title":"J Pediatr Hematol Oncol"},{"issue":"6","key":"2062_CR195","doi-asserted-by":"publisher","first-page":"685","DOI":"10.4103\/0253-7613.169576","volume":"47","author":"P Agrawal","year":"2015","unstructured":"Agrawal P, Singh O, Nigam AK, Upadhyay S. Imatinib-induced dental hyperpigmentation in chronic myeloid leukemia in an adult female. Indian J Pharmacol. 2015;47(6):685\u20136.","journal-title":"Indian J Pharmacol."},{"issue":"4","key":"2062_CR196","doi-asserted-by":"publisher","first-page":"409","DOI":"10.4103\/0378-6323.182387","volume":"82","author":"S Ghunawat","year":"2016","unstructured":"Ghunawat S, Sarkar R, Garg VK. Imatinib induced melasma-like pigmentation: report of five cases and review of literature. Indian J Dermatol Venereol Leprol. 2016;82(4):409\u201312.","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"3","key":"2062_CR197","doi-asserted-by":"publisher","first-page":"245","DOI":"10.2515\/therapie\/2014018","volume":"69","author":"I Hamza","year":"2014","unstructured":"Hamza I, Gaies E, Kastalli S, Daghfous R, El Aidli S. Facial hyperpigmentation during imatinib therapy for gastrointestinal stromal tumor. Therapie. 2014;69(3):245\u20137.","journal-title":"Therapie"},{"issue":"5","key":"2062_CR198","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1016\/j.jaad.2017.06.044","volume":"77","author":"J Dai","year":"2017","unstructured":"Dai J, Belum VR, Wu S, Sibaud V, Lacouture ME. Pigmentary changes in patients treated with targeted anticancer agents: a systematic review and meta-analysis. J Am Acad Dermatol. 2017;77(5):902-10e2.","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"2062_CR199","doi-asserted-by":"publisher","first-page":"7","DOI":"10.5070\/D3472203P2","volume":"14","author":"DT Alexandrescu","year":"2008","unstructured":"Alexandrescu DT, Dasanu CA, Farzanmehr H, Kauffman L. Persistent cutaneous hyperpigmentation after tyrosine kinase inhibition with imatinib for GIST. Dermatol Online J. 2008;14(7):7.","journal-title":"Dermatol Online J"},{"issue":"8","key":"2062_CR200","doi-asserted-by":"publisher","first-page":"e462","DOI":"10.1111\/ijd.13257","volume":"55","author":"P Espinosa Lara","year":"2016","unstructured":"Espinosa Lara P, Bueno C, Aranegui B, Vargas-Machuca I, Jimenez RJ. Yellowish nail pigmentation caused by sunitinib. Int J Dermatol. 2016;55(8):e462\u20133.","journal-title":"Int J Dermatol"},{"issue":"3","key":"2062_CR201","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1097\/SMJ.0b013e31802f01a9","volume":"100","author":"CA Dasanu","year":"2007","unstructured":"Dasanu CA, Alexandrescu DT, Dutcher J. Yellow skin discoloration associated with sorafenib use for treatment of metastatic renal cell carcinoma. South Med J. 2007;100(3):328\u201330.","journal-title":"South Med J"},{"issue":"1","key":"2062_CR202","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1200\/JCO.2005.02.2194","volume":"24","author":"S Faivre","year":"2006","unstructured":"Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol. 2006;24(1):25\u201335.","journal-title":"J Clin Oncol"},{"issue":"2","key":"2062_CR203","doi-asserted-by":"publisher","first-page":"217e1","DOI":"10.1016\/j.jaad.2014.04.013","volume":"71","author":"CM Reyes-Habito","year":"2014","unstructured":"Reyes-Habito CM, Roh EK. Cutaneous reactions to chemotherapeutic drugs and targeted therapy for cancer: Part II. Targeted therapy. J Am Acad Dermatol. 2014;71(2):217e1-311.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"2062_CR204","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0190-9622(81)70072-0","volume":"5","author":"RD Granstein","year":"1981","unstructured":"Granstein RD, Sober AJ. Drug- and heavy metal-induced hyperpigmentation. J Am Acad Dermatol. 1981;5(1):1\u201318.","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"2062_CR205","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1046\/j.1365-4362.2002.01668.x","volume":"41","author":"T Kadono","year":"2002","unstructured":"Kadono T, Inaoka T, Murayama N, Ushijima K, Nagano M, Nakamura S, et al. Skin manifestations of arsenicosis in two villages in Bangladesh. Int J Dermatol. 2002;41(12):841\u20136.","journal-title":"Int J Dermatol"},{"issue":"4","key":"2062_CR206","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1046\/j.1365-4362.1997.00101.x","volume":"36","author":"RA Schwartz","year":"1997","unstructured":"Schwartz RA. Arsenic and the skin. Int J Dermatol. 1997;36(4):241\u201350.","journal-title":"Int J Dermatol"},{"issue":"Suppl 2","key":"2062_CR207","doi-asserted-by":"publisher","first-page":"S403","DOI":"10.4103\/0975-7406.163471","volume":"7","author":"C Sreeja","year":"2015","unstructured":"Sreeja C, Ramakrishnan K, Vijayalakshmi D, Devi M, Aesha I, Vijayabanu B. Oral pigmentation: a review. J Pharm Bioallied Sci. 2015;7(Suppl 2):S403\u20138.","journal-title":"J Pharm Bioallied Sci."},{"issue":"Suppl 1","key":"2062_CR208","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1093\/clinids\/12.Supplement_1.S3","volume":"12","author":"DW Bierer","year":"1990","unstructured":"Bierer DW. Bismuth subsalicylate: history, chemistry, and safety. Rev Infect Dis. 1990;12(Suppl 1):S3-8.","journal-title":"Rev Infect Dis"},{"issue":"6","key":"2062_CR209","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1111\/j.1365-2710.1989.tb00268.x","volume":"14","author":"B Bradley","year":"1989","unstructured":"Bradley B, Singleton M, Lin Wan Po A. Bismuth toxicity\u2014a reassessment. J Clin Pharm Ther. 1989;14(6):423\u201341.","journal-title":"J Clin Pharm Ther"},{"issue":"12","key":"2062_CR210","first-page":"1132","volume":"8","author":"PR Cohen","year":"2009","unstructured":"Cohen PR. Black tongue secondary to bismuth subsalicylate: case report and review of exogenous causes of macular lingual pigmentation. J Drugs Dermatol. 2009;8(12):1132\u20135.","journal-title":"J Drugs Dermatol"},{"issue":"7","key":"2062_CR211","first-page":"968","volume":"137","author":"MD Ioffreda","year":"2001","unstructured":"Ioffreda MD, Gordon CA, Adams DR, Naides SJ, Miller JJ. Black tongue. Arch Dermatol. 2001;137(7):968\u20139.","journal-title":"Arch Dermatol"},{"issue":"8","key":"2062_CR212","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1097\/DAD.0000000000001967","volume":"43","author":"V Ravi","year":"2021","unstructured":"Ravi V, Cohen B, Kim G, Abraham JL, Sanyal S, Tran D, et al. Chrysiasis: gold aggregates around a nevus and osteoma cutis. Am J Dermatopathol. 2021;43(8):579\u201382.","journal-title":"Am J Dermatopathol"},{"issue":"2","key":"2062_CR213","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s40257-021-00588-6","volume":"22","author":"PR Cohen","year":"2021","unstructured":"Cohen PR, Ross EV. Laser-induced chrysiasis: a unique adverse event associated with Q-switched lasers. Am J Clin Dermatol. 2021;22(2):289\u201390.","journal-title":"Am J Clin Dermatol"},{"issue":"2 Pt 2","key":"2062_CR214","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/S0190-9622(07)80006-5","volume":"34","author":"CJ Fleming","year":"1996","unstructured":"Fleming CJ, Salisbury EL, Kirwan P, Painter DM, Barnetson RS. Chrysiasis after low-dose gold and UV light exposure. J Am Acad Dermatol. 1996;34(2 Pt 2):349\u201351.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"2062_CR215","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1111\/j.1365-2133.1995.tb02737.x","volume":"133","author":"RW Smith","year":"1995","unstructured":"Smith RW, Leppard B, Barnett NL, Millward-Sadler GH, McCrae F, Cawley MI. Chrysiasis revisited: a clinical and pathological study. Br J Dermatol. 1995;133(5):671\u20138.","journal-title":"Br J Dermatol"},{"issue":"3","key":"2062_CR216","first-page":"620","volume":"33","author":"H Almoallim","year":"2006","unstructured":"Almoallim H, Klinkhoff AV, Arthur AB, Rivers JK, Chalmers A. Laser induced chrysiasis: disfiguring hyperpigmentation following Q-switched laser therapy in a woman previously treated with gold. J Rheumatol. 2006;33(3):620\u20131.","journal-title":"J Rheumatol"},{"issue":"2 Suppl","key":"2062_CR217","doi-asserted-by":"publisher","first-page":"S59","DOI":"10.1016\/j.jaad.2005.12.008","volume":"55","author":"DE Geist","year":"2006","unstructured":"Geist DE, Phillips TJ. Development of chrysiasis after Q-switched ruby laser treatment of solar lentigines. J Am Acad Dermatol. 2006;55(2 Suppl):S59-60.","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"2062_CR218","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1111\/1346-8138.13617","volume":"44","author":"WJ Kwon","year":"2017","unstructured":"Kwon WJ, Lee MK, Cho HS, Kim BS, Cho EB, Park EJ, et al. Suspicious case with laser-induced chrysiasis: hyperpigmentation following laser toning with neodymium:yttrium-aluminum-garnet in a woman previously treated with microneedle therapy system using gold. J Dermatol. 2017;44(8):978\u20139.","journal-title":"J Dermatol"},{"issue":"9","key":"2062_CR219","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1007\/s10103-019-02780-x","volume":"34","author":"A AlHargan","year":"2019","unstructured":"AlHargan A, AlTalhab S, Ghobara Y, Alissa A, AlJasser MI. Effect of quality-switched laser exposure in patients with history of edible gold consumption. Lasers Med Sci. 2019;34(9):1813\u20137.","journal-title":"Lasers Med Sci"},{"issue":"3","key":"2062_CR220","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1111\/j.1524-4725.2009.01092.x","volume":"35","author":"JJ Wu","year":"2009","unstructured":"Wu JJ, Papajohn NG, Murase JE, Verkruysse W, Kelly KM. Generalized chrysiasis improved with pulsed dye laser. Dermatol Surg. 2009;35(3):538\u201342.","journal-title":"Dermatol Surg"},{"issue":"8","key":"2062_CR221","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1001\/archderm.138.8.1012","volume":"138","author":"PL Yun","year":"2002","unstructured":"Yun PL, Arndt KA, Anderson RR. Q-switched laser-induced chrysiasis treated with long-pulsed laser. Arch Dermatol. 2002;138(8):1012\u20134.","journal-title":"Arch Dermatol"},{"issue":"5","key":"2062_CR222","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1002\/lsm.22353","volume":"47","author":"AA Lloyd","year":"2015","unstructured":"Lloyd AA, Graves MS, Ross EV. Cutaneous siderosis secondary to intramuscular iron dextran treated with 755 nm Q-switched alexandrite laser: a case report. Lasers Surg Med. 2015;47(5):386\u20137.","journal-title":"Lasers Surg Med"},{"issue":"4","key":"2062_CR223","doi-asserted-by":"publisher","first-page":"348","DOI":"10.3109\/15569527.2013.875558","volume":"33","author":"E Ozlu","year":"2014","unstructured":"Ozlu E, Karadag AS, Bilgili SG, Bayram I. Cutaneous siderosis after intramuscular iron injections: a case report. Cutan Ocul Toxicol. 2014;33(4):348\u201350.","journal-title":"Cutan Ocul Toxicol"},{"issue":"6","key":"2062_CR224","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.bjhh.2015.08.012","volume":"37","author":"JR Friedrisch","year":"2015","unstructured":"Friedrisch JR, Cancado RD. Intravenous ferric carboxymaltose for the treatment of iron deficiency anemia. Rev Bras Hematol Hemoter. 2015;37(6):400\u20135.","journal-title":"Rev Bras Hematol Hemoter"},{"issue":"7","key":"2062_CR225","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1097\/DAD.0000000000002461","volume":"45","author":"A Fernandez-Flores","year":"2023","unstructured":"Fernandez-Flores A, Fernandez-Parrado M, Alzoghby-Abi Chaker J, Angulo AG. Axillary cutaneous hemosiderosis in a patient with hyperhidrosis, after intravenous iron infusion. Am J Dermatopathol. 2023;45(7):463\u20135.","journal-title":"Am J Dermatopathol"},{"issue":"5","key":"2062_CR226","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1111\/bjh.15628","volume":"184","author":"M Wong","year":"2019","unstructured":"Wong M, Bryson M. Extensive skin hyperpigmentation following intravenous iron infusion. Br J Haematol. 2019;184(5):709.","journal-title":"Br J Haematol"},{"issue":"1","key":"2062_CR227","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/archderm.1969.01610250007001","volume":"100","author":"EP Cawley","year":"1969","unstructured":"Cawley EP, Hsu YT, Wood BT, Weary PE. Hemochromatosis and the skin. Arch Dermatol. 1969;100(1):1\u20136.","journal-title":"Arch Dermatol"},{"issue":"1","key":"2062_CR228","doi-asserted-by":"publisher","first-page":"92","DOI":"10.2340\/00015555-1578","volume":"94","author":"IT Drakensjo","year":"2014","unstructured":"Drakensjo IT, Lengstam I, Hedblad MA. Skin discoloration caused by iron salts. Acta Derm Venereol. 2014;94(1):92\u20133.","journal-title":"Acta Derm Venereol"},{"issue":"5","key":"2062_CR229","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1097\/DAD.0000000000000944","volume":"40","author":"A Fernandez-Flores","year":"2018","unstructured":"Fernandez-Flores A, Bermudez CF, Molina I, Saus C, Monteagudo C, Cassarino DC. Pigmented deposits in the skin. Am J Dermatopathol. 2018;40(5):307\u201328.","journal-title":"Am J Dermatopathol"},{"issue":"6","key":"2062_CR230","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1111\/j.1365-2133.1975.tb03156.x","volume":"92","author":"BR Allen","year":"1975","unstructured":"Allen BR, Moore MR, Hunter JA. Lead and the skin. Br J Dermatol. 1975;92(6):715\u20139.","journal-title":"Br J Dermatol"},{"issue":"2","key":"2062_CR231","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1159\/000098100","volume":"57","author":"JM Pearce","year":"2007","unstructured":"Pearce JM. Burton\u2019s line in lead poisoning. Eur Neurol. 2007;57(2):118\u20139.","journal-title":"Eur Neurol"},{"issue":"10","key":"2062_CR232","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1093\/qjmed\/hcab192","volume":"114","author":"T Yamaguchi","year":"2021","unstructured":"Yamaguchi T, Yamagami K. Burton\u2019s line: a sign of chronic lead poisoning. QJM. 2021;114(10):752.","journal-title":"QJM"},{"issue":"19","key":"2062_CR233","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMicm1801693","volume":"379","author":"F Helmich","year":"2018","unstructured":"Helmich F, Lock G. Burton\u2019s line from chronic lead intoxication. N Engl J Med. 2018;379(19): e35.","journal-title":"N Engl J Med"},{"key":"2062_CR234","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/460508","volume":"2012","author":"RA Bernhoft","year":"2012","unstructured":"Bernhoft RA. Mercury toxicity and treatment: a review of the literature. J Environ Public Health. 2012;2012: 460508.","journal-title":"J Environ Public Health"},{"key":"2062_CR235","doi-asserted-by":"crossref","unstructured":"Dyall-Smith DJ, Scurry JP. Mercury pigmentation and high mercury levels from the use of a cosmetic cream. Med J Aust. 1990;153(7):409\u201310, 14\u20135.","DOI":"10.5694\/j.1326-5377.1990.tb125501.x"},{"issue":"6","key":"2062_CR236","doi-asserted-by":"publisher","first-page":"892","DOI":"10.25259\/IJDVL_888_20","volume":"87","author":"S Jagadeesan","year":"2021","unstructured":"Jagadeesan S, Duraisamy P, Panicker VV, Anjaneyan G, Sajini L, Velayudhan S, et al. Cutaneous mercury granulomas, hyperpigmentation and systemic involvement: a case of mercury toxicity following herbal medication for psoriasis. Indian J Dermatol Venereol Leprol. 2021;87(6):892.","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"4","key":"2062_CR237","doi-asserted-by":"publisher","first-page":"294","DOI":"10.2340\/0001555572294296","volume":"72","author":"K Schrallhammer-Benkler","year":"1992","unstructured":"Schrallhammer-Benkler K, Ring J, Przybilla B, Meurer M, Landthaler M. Acute mercury intoxication with lichenoid drug eruption followed by mercury contact allergy and development of antinuclear antibodies. Acta Derm Venereol. 1992;72(4):294\u20136.","journal-title":"Acta Derm Venereol"},{"issue":"1 Pt 1","key":"2062_CR238","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1067\/mjd.2000.106360","volume":"43","author":"AS Boyd","year":"2000","unstructured":"Boyd AS, Seger D, Vannucci S, Langley M, Abraham JL, King LE Jr. Mercury exposure and cutaneous disease. J Am Acad Dermatol. 2000;43(1 Pt 1):81\u201390.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"2062_CR239","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s40257-015-0126-8","volume":"16","author":"BJ Simmons","year":"2015","unstructured":"Simmons BJ, Griffith RD, Bray FN, Falto-Aizpurua LA, Nouri K. Exogenous ochronosis: a comprehensive review of the diagnosis, epidemiology, causes, and treatments. Am J Clin Dermatol. 2015;16(3):205\u201312.","journal-title":"Am J Clin Dermatol"},{"issue":"4","key":"2062_CR240","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1067\/S0190-9622(02)61574-9","volume":"49","author":"NM Fisher","year":"2003","unstructured":"Fisher NM, Marsh E, Lazova R. Scar-localized argyria secondary to silver sulfadiazine cream. J Am Acad Dermatol. 2003;49(4):730\u20132.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"2062_CR241","doi-asserted-by":"publisher","first-page":"308","DOI":"10.5021\/ad.2009.21.3.308","volume":"21","author":"HB Kwon","year":"2009","unstructured":"Kwon HB, Lee JH, Lee SH, Lee AY, Choi JS, Ahn YS. A case of argyria following colloidal silver ingestion. Ann Dermatol. 2009;21(3):308\u201310.","journal-title":"Ann Dermatol"},{"issue":"3","key":"2062_CR242","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1046\/j.1365-2230.2003.01214.x","volume":"28","author":"JM White","year":"2003","unstructured":"White JM, Powell AM, Brady K, Russell-Jones R. Severe generalized argyria secondary to ingestion of colloidal silver protein. Clin Exp Dermatol. 2003;28(3):254\u20136.","journal-title":"Clin Exp Dermatol"},{"issue":"5","key":"2062_CR243","doi-asserted-by":"publisher","first-page":"413","DOI":"10.2340\/0001555557413419","volume":"57","author":"G Plewig","year":"1977","unstructured":"Plewig G, Lincke H, Wolff HH. Silver-blue nails. Acta Derm Venereol. 1977;57(5):413\u20139.","journal-title":"Acta Derm Venereol"},{"issue":"7","key":"2062_CR244","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1046\/j.1365-4362.2003.01899.x","volume":"42","author":"JK McKenna","year":"2003","unstructured":"McKenna JK, Hull CM, Zone JJ. Argyria associated with colloidal silver supplementation. Int J Dermatol. 2003;42(7):549.","journal-title":"Int J Dermatol"},{"issue":"1","key":"2062_CR245","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s00347-019-0899-x","volume":"117","author":"D Claessens","year":"2020","unstructured":"Claessens D, Zeitz PF, Beckers H. Bluish-gray discoloration of skin and conjunctiva. Ophthalmologe. 2020;117(1):66\u20138.","journal-title":"Ophthalmologe"},{"issue":"7","key":"2062_CR246","doi-asserted-by":"publisher","first-page":"e115","DOI":"10.1097\/DAD.0b013e318284e37b","volume":"35","author":"CM McClain","year":"2013","unstructured":"McClain CM, Kantrow SM, Abraham JL, Price J, Parker ER, Robbins JB. Localized cutaneous argyria: two case reports and clinicopathologic review. Am J Dermatopathol. 2013;35(7):e115\u20138.","journal-title":"Am J Dermatopathol"},{"issue":"8","key":"2062_CR247","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1111\/jocd.13549","volume":"19","author":"A Almurayshid","year":"2020","unstructured":"Almurayshid A, Park S, Oh SH. Effective laser treatment options for argyria: review of literatures. J Cosmet Dermatol. 2020;19(8):1877\u201382.","journal-title":"J Cosmet Dermatol"},{"issue":"2","key":"2062_CR248","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.det.2018.12.008","volume":"37","author":"R Zubair","year":"2019","unstructured":"Zubair R, Lyons AB, Vellaichamy G, Peacock A, Hamzavi I. What\u2019s new in pigmentary disorders. Dermatol Clin. 2019;37(2):175\u201381.","journal-title":"Dermatol Clin"},{"issue":"7","key":"2062_CR249","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1111\/jdv.13176","volume":"30","author":"AK Jha","year":"2016","unstructured":"Jha AK, Sinha R, Prasad S, Nandan N. Bimatoprost in periorbital vitiligo: a ray of hope or dilemma. J Eur Acad Dermatol Venereol. 2016;30(7):1247\u20138.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"2062_CR250","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1001\/archophthalmol.2010.89","volume":"128","author":"JC Priluck","year":"2010","unstructured":"Priluck JC, Fu S. Latisse-induced periocular skin hyperpigmentation. Arch Ophthalmol. 2010;128(6):792\u20133.","journal-title":"Arch Ophthalmol"},{"issue":"4","key":"2062_CR251","doi-asserted-by":"publisher","first-page":"925","DOI":"10.3906\/sag-1405-23","volume":"45","author":"MZ Karslioglu","year":"2015","unstructured":"Karslioglu MZ, Hosal MB, Tekeli O. Periocular changes in topical bimatoprost and latanoprost use. Turk J Med Sci. 2015;45(4):925\u201330.","journal-title":"Turk J Med Sci."},{"issue":"12","key":"2062_CR252","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1080\/02713680701750625","volume":"32","author":"ED Sharpe","year":"2007","unstructured":"Sharpe ED, Reynolds AC, Skuta GL, Jenkins JN, Stewart WC. The clinical impact and incidence of periocular pigmentation associated with either latanoprost or bimatoprost therapy. Curr Eye Res. 2007;32(12):1037\u201343.","journal-title":"Curr Eye Res"},{"issue":"11","key":"2062_CR253","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1001\/archopht.123.11.1541","volume":"123","author":"R Kapur","year":"2005","unstructured":"Kapur R, Osmanovic S, Toyran S, Edward DP. Bimatoprost-induced periocular skin hyperpigmentation: histopathological study. Arch Ophthalmol. 2005;123(11):1541\u20136.","journal-title":"Arch Ophthalmol"},{"issue":"7","key":"2062_CR254","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1038\/sj.eye.6701663","volume":"19","author":"SY Chou","year":"2005","unstructured":"Chou SY, Chou CK, Kuang TM, Hsu WM. Incidence and severity of iris pigmentation on latanoprost-treated glaucoma eyes. Eye (Lond). 2005;19(7):784\u20137.","journal-title":"Eye (Lond)"},{"issue":"5","key":"2062_CR255","doi-asserted-by":"publisher","first-page":"546","DOI":"10.2340\/00015555-0697","volume":"89","author":"M Blomberg","year":"2009","unstructured":"Blomberg M, Zachariae CO, Gronhoj F. Hyperpigmentation of the face following adalimumab treatment. Acta Derm Venereol. 2009;89(5):546\u20137.","journal-title":"Acta Derm Venereol"},{"issue":"3","key":"2062_CR256","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1111\/ijd.15268","volume":"60","author":"F Gil","year":"2021","unstructured":"Gil F, Andrade I, Aranha J. Hyperpigmentation as a rare side effect of adalimumab. Int J Dermatol. 2021;60(3):e105\u20136.","journal-title":"Int J Dermatol"},{"issue":"4","key":"2062_CR257","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.clindermatol.2006.04.006","volume":"24","author":"LK Nieman","year":"2006","unstructured":"Nieman LK, Chanco Turner ML. Addison\u2019s disease. Clin Dermatol. 2006;24(4):276\u201380.","journal-title":"Clin Dermatol"},{"issue":"8","key":"2062_CR258","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2021-245610","volume":"14","author":"CV Tong","year":"2021","unstructured":"Tong CV, Ooi XY. Addison\u2019s disease presenting with hyperpigmentation. BMJ Case Rep. 2021;14(8): e245610.","journal-title":"BMJ Case Rep"},{"key":"2062_CR259","unstructured":"Iyengar B, Misra RS, Subalakshmi. ACTH acts directly on melanocytes to stimulate melanogenesis\u2014an in vitro study. Indian J Pathol Microbiol. 1995;38(4):399\u2013402."},{"issue":"6","key":"2062_CR260","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1111\/bjd.13598","volume":"172","author":"G Biolcati","year":"2015","unstructured":"Biolcati G, Marchesini E, Sorge F, Barbieri L, Schneider-Yin X, Minder EI. Long-term observational study of afamelanotide in 115 patients with erythropoietic protoporphyria. Br J Dermatol. 2015;172(6):1601\u201312.","journal-title":"Br J Dermatol"},{"issue":"1","key":"2062_CR261","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1001\/2013.jamadermatol.386","volume":"149","author":"PE Grimes","year":"2013","unstructured":"Grimes PE, Hamzavi I, Lebwohl M, Ortonne JP, Lim HW. The efficacy of afamelanotide and narrowband UV-B phototherapy for repigmentation of vitiligo. JAMA Dermatol. 2013;149(1):68\u201373.","journal-title":"JAMA Dermatol"},{"issue":"2","key":"2062_CR262","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1111\/j.1365-2133.2010.10104.x","volume":"164","author":"AK Haylett","year":"2011","unstructured":"Haylett AK, Nie Z, Brownrigg M, Taylor R, Rhodes LE. Systemic photoprotection in solar urticaria with alpha-melanocyte-stimulating hormone analogue [Nle4-D-Phe7]-alpha-MSH. Br J Dermatol. 2011;164(2):407\u201314.","journal-title":"Br J Dermatol"},{"issue":"3","key":"2062_CR263","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.jdermsci.2009.06.003","volume":"55","author":"ZM Hu","year":"2009","unstructured":"Hu ZM, Zhou Q, Lei TC, Ding SF, Xu SZ. Effects of hydroquinone and its glucoside derivatives on melanogenesis and antioxidation: Biosafety as skin whitening agents. J Dermatol Sci. 2009;55(3):179\u201384.","journal-title":"J Dermatol Sci"},{"issue":"10","key":"2062_CR264","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1001\/archderm.1985.01660100019003","volume":"121","author":"NS Penneys","year":"1985","unstructured":"Penneys NS. Ochronosislike pigmentation from hydroquinone bleaching creams. Arch Dermatol. 1985;121(10):1239\u201340.","journal-title":"Arch Dermatol"},{"issue":"5","key":"2062_CR265","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1002\/jimd.12152","volume":"42","author":"LR Ranganath","year":"2019","unstructured":"Ranganath LR, Norman BP, Gallagher JA. Ochronotic pigmentation is caused by homogentisic acid and is the key event in alkaptonuria leading to the destructive consequences of the disease\u2014a review. J Inherit Metab Dis. 2019;42(5):776\u201392.","journal-title":"J Inherit Metab Dis"},{"issue":"4","key":"2062_CR266","doi-asserted-by":"publisher","first-page":"213","DOI":"10.2165\/00128071-200102040-00002","volume":"2","author":"CY Levin","year":"2001","unstructured":"Levin CY, Maibach H. Exogenous ochronosis. An update on clinical features, causative agents and treatment options. Am J Clin Dermatol. 2001;2(4):213\u20137.","journal-title":"Am J Clin Dermatol"},{"issue":"9","key":"2062_CR267","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1001\/jama.1967.03120090043007","volume":"199","author":"S Resnik","year":"1967","unstructured":"Resnik S. Melasma induced by oral contraceptive drugs. JAMA. 1967;199(9):601\u20135.","journal-title":"JAMA"},{"key":"2062_CR268","first-page":"101","volume":"21","author":"SS Resnik","year":"1967","unstructured":"Resnik SS. Melasma and other skin manifestations or oral contraceptives. Trans N Engl Obstet Gynecol Soc. 1967;21:101\u20137.","journal-title":"Trans N Engl Obstet Gynecol Soc"},{"issue":"5","key":"2062_CR269","doi-asserted-by":"publisher","first-page":"624","DOI":"10.2340\/00015555-2013","volume":"95","author":"N Locci-Molina","year":"2015","unstructured":"Locci-Molina N, Wang A, Kroumpouzos G. Melasma improving spontaneously upon switching from a combined oral contraceptive to a hormone-releasing intrauterine device: a report of four cases. Acta Derm Venereol. 2015;95(5):624\u20135.","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"2062_CR270","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1177\/000992288102000103","volume":"20","author":"AD Lascari","year":"1981","unstructured":"Lascari AD. Carotenemia. A review. Clin Pediatr (Phila). 1981;20(1):25\u20139.","journal-title":"Clin Pediatr (Phila)"},{"key":"2062_CR271","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.clnesp.2017.12.002","volume":"23","author":"AMB Priyadarshani","year":"2018","unstructured":"Priyadarshani AMB. Insights of hypercarotenaemia: a brief review. Clin Nutr ESPEN. 2018;23:19\u201324.","journal-title":"Clin Nutr ESPEN."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-024-02062-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-024-02062-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-024-02062-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T12:14:18Z","timestamp":1732536858000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-024-02062-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,1]]},"references-count":271,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["2062"],"URL":"https:\/\/doi.org\/10.1007\/s40265-024-02062-z","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,1]]},"assertion":[{"value":"4 June 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Drs Tisack and Mohammad have no conflicts of interest\u00a0to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"N\/A.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"N\/A.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"N\/A.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for participation\/publication"}},{"value":"N\/A.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"The senior author, Tasneem F. Mohammad, initiated this review. Aaron Tisack performed the literature search and wrote the initial draft. Both authors revised the manuscript and read and approved the final manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}